<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">101584</article-id><article-id pub-id-type="doi">10.7554/eLife.101584</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101584.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Causal associations between human plasma proteins and prostate cancer identified by proteome-wide Mendelian randomization</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Yanlun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yuke</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhou</surname><given-names>Ying</given-names></name><email>zhouying0321@126.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rong</surname><given-names>Zhuona</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0636-9477</contrib-id><email>rongzhuona@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pang</surname><given-names>Xiaocong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5951-5944</contrib-id><email>pangxiaocong1227@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02v51f717</institution-id><institution>Department of Pharmacy, Peking University First Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02v51f717</institution-id><institution>School of Pharmaceutical Sciences, Peking University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02v51f717</institution-id><institution>Department of Urology, Peking University First Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cullen</surname><given-names>Jennifer</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051fd9666</institution-id><institution>Case Western Reserve University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>11</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP101584</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-08-26"><day>26</day><month>08</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-09-18"><day>18</day><month>09</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.09.17.24312688"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-05-12"><day>12</day><month>05</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101584.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-10-21"><day>21</day><month>10</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101584.2"/></event></pub-history><permissions><copyright-statement>© 2025, Chen et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-101584-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-101584-figures-v1.pdf"/><abstract><p>Prostate cancer (PCa) diagnosis is hampered by the limited specificity of current methods, necessitating more reliable biomarkers. To identify causal protein biomarkers and therapeutic targets in humans, we conducted a proteome-wide Mendelian randomization (MR) study. We first performed a meta-analysis of two independent genome-wide association studies, including 94,397 individuals with PCa and 192,372 controls, which identified five possible susceptibility loci (JAZF1, PDILM5, WDPCP, EEFSEC, TNS3) for PCa. Subsequently, MR and colocalization analyses were performed using genetic instruments for 4907 plasma proteins from deCODE Genetics (N=35,559) and 2940 plasma proteins from UK Biobank Pharma Proteomics Project (UKB-PPP) (N=54,219). Among 3722 human proteins analyzed, 193 were associated with PCa risk, with 20 high-risk proteins (including KLK3) validated across both cohorts. Functional annotation implicated immune and inflammatory responses and cell–cell interaction pathways. Druggability analyses nominated several potential drug targets for PCa, such as HSPB1, RRM2B, and PSCA. Our findings reveal novel risk loci and candidate protein biomarkers, providing new etiological insights and potential avenues for PCa early detection and therapy.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>prostate cancer</kwd><kwd>proteins</kwd><kwd>biomarkers</kwd><kwd>Mendelian randomization</kwd><kwd>colocalization analysis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Beijing Municipal Natural Science Foundation</institution></institution-wrap></funding-source><award-id>JQ24059</award-id><principal-award-recipient><name><surname>Pang</surname><given-names>Xiaocong</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Beijing Municipal Natural Science Foundation</institution></institution-wrap></funding-source><award-id>L234038</award-id><principal-award-recipient><name><surname>Pang</surname><given-names>Xiaocong</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Beijing Municipal Natural Science Foundation</institution></institution-wrap></funding-source><award-id>L248076</award-id><principal-award-recipient><name><surname>Rong</surname><given-names>Zhuona</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82274015</award-id><principal-award-recipient><name><surname>Pang</surname><given-names>Xiaocong</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The identification of 20 causal plasma proteins for prostate cancer represents a critical step toward addressing the need for improved diagnostic specificity and reveals promising new targets for therapeutic intervention.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Prostate cancer (PCa) is the second most common malignancy with an estimation of 1.5 million new cases in 2022, which is accounted for 14% of total cancer diagnosed in men worldwide (<xref ref-type="bibr" rid="bib18">Ferlay et al., 2024</xref>). Even more worrying is that the number of new cases of PCa is projected to 2.9 million by 2040 (<xref ref-type="bibr" rid="bib37">James et al., 2024</xref>). Despite advancements in medical technology, early detection of PCa remains a significant challenge due to the limitations in specificity of current diagnostic methods, such as prostate-specific antigen (PSA) testing (<xref ref-type="bibr" rid="bib39">Kalavacherla et al., 2023</xref>; <xref ref-type="bibr" rid="bib72">Tikkinen et al., 2018</xref>). Therefore, there is an urgent need for more accurate and reliable biomarkers that can improve early detection and prognostic evaluations of PCa.</p><p>Plasma proteins have key roles in the development and progression of PCa, such as interleukin (IL)-6 (<xref ref-type="bibr" rid="bib12">Deichaite et al., 2022</xref>), insulin-like growth factor (IGF)-1, and IGF-binding protein (IGFBP)-1 (<xref ref-type="bibr" rid="bib5">Cao et al., 2015</xref>). However, observational studies exploring the association between plasma proteins and PCa risk are often limited by confounding factors and selection bias, making it challenging to establish a clear causal relationship.</p><p>To overcome these limitations, Mendelian randomization (MR) offers a robust methodological approach. This approach utilizes the principle of random assortment of genes from parents to offspring, using genetic variation as an instrumental variable, which mimics the randomization process in a controlled trial, thereby minimizing the impact of reverse causality (<xref ref-type="bibr" rid="bib11">Davies et al., 2018</xref>). With the recent development of proteomics technology, several large-scale proteomic studies have identified over 18,000 protein quantitative trait loci (pQTLs) covering more than 4800 proteins (<xref ref-type="bibr" rid="bib17">Ferkingstad et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Pietzner et al., 2021</xref>). By using MR, researchers can gain a deeper comprehension of whether particular plasma proteins hold a causal nexus with PCa, thereby potentially unraveling novel biomarkers and targets for the prevention and treatment of PCa.</p><p>In this study, we performed a meta-analysis of two genome-wide association studies (GWAS) on PCa (PRACTICAL and FinnGen) for a total sample size of 94,397 cases and 192,372 controls. Based on GWAS summary statistics data from deCODE and UKB-PPP cohorts, we further performed a protein-wide MR (PW-MR) study, supplemented by colocalization analysis, to explore the causal relationship between plasma proteins and PCa risk. Moreover, we indicated biological processes and pathways associated with PCa, and evaluated the druggability of risk proteins. We aimed to identify novel plasma protein biomarkers for PCa, which could address the limitations of current diagnostic methods and offer new insights into the biological mechanisms of PCa and potential therapeutic targets for intervention (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Flowchart of the study design for the protein-wide Mendelian randomization (PW-MR) analysis of prostate cancer (PCa).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig1-v1.tif"/></fig></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Meta-analysis of the genome-wide association studies for prostate cancer</title><p>We conducted a meta-analysis combining two GWASs with a collective sample size of 94,397 individuals with PCa and 192,372 controls, aiming to identify genetic variants linked to PCa. The associations and assessment of Single Nucleotide Polymorphisms (SNPs) heterogeneity that passed the genome-wide <italic>P</italic>-value threshold at these loci with PCa are presented in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref>. We found five genetic risk loci contained at least one SNP passing the genome-wide significance threshold of <italic>P</italic>≤5 × 10<sup>−8</sup>: JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3 (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Among them, PDLIM5, WDPCP, EEFSEC, and TNS3 were promising candidates as novel susceptibility loci associated with PCa. <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> displays the associated quantile–quantile plot. The LocusZoom plots of the top SNPs at JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3, along with their genomic location, GWAS <italic>P</italic> values, and recombination rate with neighboring SNPs are visualized in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>. In summary, this GWAS meta-analysis discovered genetic variations in one recognized PC-associated locus and four potential novel loci, providing a reliable dataset for MR analyses.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Manhattan plot of prostate cancer (PCa) genome-wide association studies (GWASs) meta-analysis.</title><p>The genetic regions containing top SNPs related to PCa are depicted. The red dashed line signifies the genome-wide significance threshold of 5.0×10<sup>−8</sup>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Quantile–quantile plot of the prostate cancer (PCa) genome-wide association studies (GWASs).</title><p>The quantile–quantile plot illustrates the discrepancy between the actual <italic>P</italic> values of GWAS SNPs and the expected <italic>P</italic> values from a theoretical χ<sup>2</sup> distribution.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>LocusZoom plots of genome-wide association studies (GWASs) top SNPs.</title><p>Genetic loci harboring top SNPs at the (<bold>A</bold>) JAZF1, (<bold>B</bold>) PDILM5, (<bold>C</bold>) WDPCP, (<bold>D</bold>) EEFSEC, and (<bold>E</bold>) TNS3 loci are displayed. LD value with the top SNP is represented by colors spanning from dark blue (low) to red (high). The dashed gray line represents the genome-wide significance threshold of 5×10<sup>–8</sup>. Neighboring genes are shown at the bottom of the figure.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig2-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Cross-phenotype analysis of prostate cancer</title><p>The cross-phenotype analysis was designed to systematically identify phenotypic traits that share genetic or molecular pathways with PCa, thereby uncovering pleiotropic mechanisms or shared risk factors. We used the iCPAGdb to conduct this analysis with PCa genome-wide significant SNPs (<italic>P</italic>≤5 × 10<sup>−8</sup>). The iCPAGdb offered an improved algorithm for identifying cross-phenotype associations by using pre-computed ancestry-specific LD databases and integrating genetic data from 3793 traits in the NHGRI-EBI GWAS catalog (<xref ref-type="bibr" rid="bib76">Wang et al., 2020</xref>). Cross-phenotype analysis of PCa-associated SNPs identified 117 traits significantly linked to PCa after Bonferroni’s correction (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1B</xref>). As shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>, the strong association with PSA measurement (<italic>P</italic>=7.16 × 10<sup>–43</sup>) validated our genetic instruments, while the enrichment of metabolic traits such as BMI-adjusted waist–hip ratio (WHR) (<italic>P</italic>=1.32 × 10<sup>–26</sup>), high-density lipoprotein (HDL) cholesterol measurement (<italic>P</italic>=2.38 × 10<sup>–22</sup>), and body mass index (<italic>P</italic>=1.71 × 10<sup>–20</sup>) aligned with epidemiological evidence linking obesity to aggressive PCa. Notably, the strong association with balding (<italic>P</italic>=3.01 × 10<sup>–22</sup>) reinforced the androgen axis in PCa pathogenesis and the correlation with heel bone mineral density (<italic>P</italic>=2.02 × 10<sup>–19</sup>) was consistent with the clinical observations of osteoblastic bone metastasis in advanced PCa. These cross-phenotype associations collectively highlight PCa as a systemic disorder involving androgen signaling, metabolic dysregulation, and skeletal interactions, providing novel insights into its multifactorial etiology.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The top 10 significant cross-phenotype associations with prostate cancer (PCa) at a 5% false discovery rate (FDR).</title><p>The x-axis represents the <italic>P</italic> value of the correlation. BMI, body mass index.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig3-v1.tif"/></fig></sec><sec id="s2-3"><title>Proteome-wide Mendelian randomization studies of prostate cancer</title><p>The genetic association summary statistics of 35,559 Icelanders from deCODE Genetics and 54,219 Europeans from the UKB-PPP were utilized to investigate the relationship between PCa and plasma proteins. Our genetic instrument selection strategy enabled us to examine 1778 and 1944 proteins from deCODE and UKB-PPP (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1C and D</xref>). Using the Wald ratio or inverse-variance weighted (IVW) method, a total of 193 unique plasma proteins were significantly associated with PCa after multiple tests with a 5% false discovery rate (FDR) correction. This analysis yielded 137 proteins in UKB-PPP more than 76 proteins in deCODE (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The results of the heterogeneity test based on Q statistics showed little evidence of heterogeneity. Furthermore, no significant intercept was detected, implying that there was no directional pleiotropy observed.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Result of protein-wide Mendelian randomization (PW-MR) on the associations between plasma proteins and the risk of prostate cancer (PCa).</title><p>(<bold>A</bold>) Volcano plot of PCa PW-MR study using deCODE (the left side) and UKB-PPP (the right side) cohorts. Annotated proteins passed the 5% false discovery rate (FDR) IVW <italic>P</italic>-value threshold. The blue and red colors represent a negative and positive effect, respectively. (<bold>B</bold>) Venn diagram depicting proteins associated with PCa in deCODE and UKB-PPP. (<bold>C</bold>) PhenoGram of PCa PW-MR study significant associations. The blue dots and the green dots represent the deCODE and UKB-PPP-specific proteins, respectively. The red dot represents both simultaneously.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig4-v1.tif"/></fig><p>After FDR correction, 20 proteins were detected in both data sets and the identified associations were consistent (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Genetic prediction indicated that 11 of these 20 proteins were positively associated with the risk of PCa, as well as the remaining 9 proteins were negatively associated, suggesting that these 9 proteins may be protective factors against PCa (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>). A PhenoGram depicts the chromosomal location of the 193 unique identified proteins in deCODE and UKB-PPP studies (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p></sec><sec id="s2-4"><title>Colocalization analysis</title><p>We performed colocalization analyses of proteins significantly expressed in deCODE and UKB-PPP studies with PCa. It was observed that four proteins in the deCODE study and seven proteins in the UKB-PPP were colocalized with PCa associations with high support of evidence (PPH4≥0.8) (<xref ref-type="table" rid="table1">Table 1</xref>), suggesting that these 10 plasma proteins might serve as potential targets for treating PCa. Among them, SERPINA3 showed strong colocalization evidence in both deCODE (PPH4=0.952) and UKB-PPP (PPH4=0.951) studies. This analysis identified one causal variant in deCODE (rs61976125) and one causal variant in Fenland (rs6575449) (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Analysis of Mendelian randomization and colocalization of significant proteins with prostate cancer.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2">Genome-wide association studies</th><th align="left" valign="top" rowspan="2">Outcomes</th><th align="left" valign="top" rowspan="2">Proteins</th><th align="left" valign="top" colspan="3">Mendelian randomization</th><th align="left" valign="top" rowspan="2">Colocalization analysis PH4</th></tr><tr><th align="left" valign="top">OR (95% CI)</th><th align="left" valign="top"><italic>P</italic> value</th><th align="left" valign="top"><italic>P</italic> value after false discovery rate adjustment</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="4">deCODE</td><td align="left" valign="top" rowspan="4">Prostate cancer</td><td align="left" valign="top">MSMB</td><td align="char" char="." valign="top">0.86 (0.84,0.88)</td><td align="char" char="hyphen" valign="top">1.56E-27</td><td align="char" char="hyphen" valign="top">2.82E-24</td><td align="char" char="." valign="top">0.999</td></tr><tr><td align="left" valign="top">POGLUT3</td><td align="char" char="." valign="top">0.89 (0.83,0.96)</td><td align="char" char="hyphen" valign="top">1.16E-03</td><td align="char" char="hyphen" valign="top">2.44E-02</td><td align="char" char="." valign="top">0.998</td></tr><tr><td align="left" valign="top">PRSS3</td><td align="char" char="." valign="top">0.93 (0.91,0.94)</td><td align="char" char="hyphen" valign="top">1.00E-18</td><td align="char" char="hyphen" valign="top">6.03E-16</td><td align="char" char="." valign="top">0.956</td></tr><tr><td align="left" valign="top">SERPINA3</td><td align="char" char="." valign="top">1.11 (1.06,1.15)</td><td align="char" char="hyphen" valign="top">7.18E-08</td><td align="char" char="hyphen" valign="top">1.05E-05</td><td align="char" char="." valign="top">0.952</td></tr><tr><td align="left" valign="top" rowspan="7">UKB-PPP</td><td align="left" valign="top" rowspan="7">Prostate cancer</td><td align="left" valign="top">USP28</td><td align="char" char="." valign="top">0.47 (0.40,0.56)</td><td align="char" char="hyphen" valign="top">7.27E-17</td><td align="char" char="hyphen" valign="top">2.89E-14</td><td align="char" char="." valign="top">0.999</td></tr><tr><td align="left" valign="top">KLK3</td><td align="char" char="." valign="top">9.70 (4.94,19.03)</td><td align="char" char="hyphen" valign="top">3.83E-11</td><td align="char" char="hyphen" valign="top">6.91E-09</td><td align="char" char="." valign="top">0.999</td></tr><tr><td align="left" valign="top">IGFBP3</td><td align="char" char="." valign="top">1.07 (1.05,1.09)</td><td align="char" char="hyphen" valign="top">2.04E-11</td><td align="char" char="hyphen" valign="top">4.49E-09</td><td align="char" char="." valign="top">0.997</td></tr><tr><td align="left" valign="top">CASP10</td><td align="char" char="." valign="top">1.22 (1.11,1.34)</td><td align="char" char="hyphen" valign="top">4.73E-05</td><td align="char" char="hyphen" valign="top">1.54E-03</td><td align="char" char="." valign="top">0.988</td></tr><tr><td align="left" valign="top">HDGF</td><td align="char" char="." valign="top">0.96 (0.95,0.97)</td><td align="char" char="hyphen" valign="top">2.61E-17</td><td align="char" char="hyphen" valign="top">1.29E-14</td><td align="char" char="." valign="top">0.966</td></tr><tr><td align="left" valign="top">SERPINA3</td><td align="char" char="." valign="top">1.10 (1.07,1.13)</td><td align="char" char="hyphen" valign="top">1.64E-10</td><td align="char" char="hyphen" valign="top">2.32E-08</td><td align="char" char="." valign="top">0.951</td></tr><tr><td align="left" valign="top">C5</td><td align="char" char="." valign="top">1.19 (1.11,1.27)</td><td align="char" char="hyphen" valign="top">5.32E-07</td><td align="char" char="hyphen" valign="top">4.06E-05</td><td align="char" char="." valign="top">0.883</td></tr></tbody></table><table-wrap-foot><fn><p>OR, odds ratio; CI, confidence interval; </p></fn></table-wrap-foot></table-wrap><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Colocalization plot of SERPINA3 variants associated with prostate cancer (PCa) in deCODE and UKB-PPP.</title><p>Variants are color-coded based on their linkage disequilibrium (LD) with the lead SNP (the variant with the lowest <italic>P</italic>-value). The lead SNP is highlighted in red. Other variants are colored from blue to yellow, indicating decreasing LD with the lead SNP.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig5-v1.tif"/></fig></sec><sec id="s2-5"><title>Gene-based association and pathway analyses</title><p>We used the GENE2FUNC tool available in FUMA to explore the biological significance, functional implications, and tissue-specific expression of the genes identified from our GWAS. These genes appeared to be significantly enriched in inflammatory and immune pathways (such as defense, immune, and inflammatory response), as well as cell interaction and signaling pathways (such as interaction between organism and cell adhesion) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The Kyoto Encyclopedia of Genes and Genomes KEGG0 pathway enrichment analysis revealed several pathways that were significantly enriched, such as cytokine–cytokine receptor interaction, p53 signaling pathway, JAK-STAT signaling pathway, pathways in cancer, and apoptosis (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). These analyses indicated potential biological processes and mechanisms associated with PCa. The 193 unique genes were predominantly expressed in the lymphocytes, blood, liver, and prostate (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Functional annotation of the genetic architecture of prostate cancer (PCa).</title><p>(<bold>A</bold>) Biological processes and (<bold>B</bold>) KEGG pathway analysis of the 193 unique proteins identified in deCODE and UKB-PPP.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Gene expression heat map of the 193 unique protein-wide Mendelian randomization (PW-MR) significant proteins in deCODE and UKB-PPP.</title><p>Log2-transformed average expression in 54 GTEx v8 tissues.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101584-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Druggability of identified proteins</title><p>Exploring new therapeutic opportunities for PCa based on genetic information is crucial for developing targeted treatments. In our study, we examined the druggability of genes and proteins identified in MR analyses using OpenTargets databases. We investigated 128 unique drugs targeting 45 identified proteins (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1F</xref>). Among these, three drugs (APATORSEN, TRIAPINE, and MK-4721) currently in clinical trials were intended for PCa treatment, with each targeting HSPB1, RRM2B, and PSCA, respectively. Notably, the effects of these drugs on their respective protein targets align with the directions indicated by our MR results, suggesting a consistency between genetic evidence and therapeutic potential. In addition, several other identified targets, such as RET, FGFR3, NCAM1, TYMP, TNFRSF10B, MMP3, TACSTD2, and NOTCH2, were implicated in various cancers and present potential therapeutic avenues.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Genetic susceptibility loci and functional mechanisms</title><p>In this study, we conducted a comprehensive meta-analysis of two GWAS for PCa, identifying significant genetic loci associated with PCa risk. The combined sample size of 94,397 cases and 192,372 controls revealed one known (JAZF1) and four potential novel (PDLIM5, WDPCP, EEFSEC, and TNS3) susceptibility loci of PCa. These genetic findings not only expand our understanding of PCa heritability but also bridge the gap between genetic risk and downstream molecular mechanisms.</p><p>JAZF1, a transcriptional repressor linked to metabolic regulation (<xref ref-type="bibr" rid="bib61">Rosario et al., 2023</xref>) and cellular proliferation (<xref ref-type="bibr" rid="bib71">Sung et al., 2018</xref>), has been implicated in both type 2 diabetes and PCa risk through GWAS (<xref ref-type="bibr" rid="bib48">Machiela et al., 2012</xref>; <xref ref-type="bibr" rid="bib63">Sánchez-Maldonado et al., 2022</xref>). Its dual role highlights the interaction between metabolic dysregulation and oncogenesis, indicating that interventions targeting metabolic pathways may hold therapeutic promise for PCa.</p><p>PDLIM5 (PDZ and LIM domain 5), a cytoskeleton-associated protein, regulates cell migration and tumor progression by binding a variety of proteins through its specific domains. In PCa, PDLIM5 promotes epithelial–mesenchymal transition and migration of PCa cells (<xref ref-type="bibr" rid="bib46">Liu et al., 2017</xref>), while downregulating the expression of PDLIM5 may ultimately impede the progression of PCa (<xref ref-type="bibr" rid="bib79">Xie et al., 2020</xref>), indicating its potential value in predicting the risk of advanced PCa. WDPCP, a key effector of planar cell polarity (PCP) signaling, regulates actin cytoskeleton to maintain tissue architecture (<xref ref-type="bibr" rid="bib10">Cui et al., 2013</xref>). Disruption of PCP signaling can cause abnormal cell behavior and tissue structure, leading to the development of cancer (<xref ref-type="bibr" rid="bib33">Humphries and Mlodzik, 2018</xref>). EEFSEC is a member of the eukaryotic family of elongation factors, and its role in tumor cells has been rarely reported. A functional study demonstrated that EEFSEC was significantly upregulated in PCa cells, and high expression of EEFSEC was associated with poor prognosis in patients with PCa (<xref ref-type="bibr" rid="bib81">Xu et al., 2021</xref>). TNS3 promotes cell migration and invasion through focal adhesion dynamics (<xref ref-type="bibr" rid="bib7">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Martuszewska et al., 2009</xref>; <xref ref-type="bibr" rid="bib83">Zheng et al., 2021</xref>; <xref ref-type="bibr" rid="bib85">Zuidema et al., 2022</xref>), which is critical in cancer metastasis. While these loci implicate diverse pathways, their collective impact may converge on tumor microenvironment (TME) reprogramming. To determine whether these four genes are causative factors for PCa, genetic association studies with a larger sample size will be needed.</p></sec><sec id="s3-2"><title>Multifactorial drivers of prostate cancer</title><p>PCa arises from a complex interplay of genetic, metabolic, and hormonal perturbations. In the cross-phenotype analysis of PCa, we found multiple risk-associated traits, including proteomic biomarkers (PSA), metabolic dysregulation (central obesity, HDL dysfunction, hypertension), and androgen signaling (balding), collectively underscoring PCa’s multifactorial etiology.</p><p>PSA, a protein secreted by both normal and malignant prostate epithelial cells, has long been a cornerstone in the early detection and monitoring of PCa. However, the specificity and sensitivity of PSA as a diagnostic tool have been questioned due to its elevation in benign conditions such as prostatitis and benign prostatic hyperplasia (BPH), leading to unnecessary biopsies and substantial overdiagnosis (<xref ref-type="bibr" rid="bib24">Gudmundsson et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Ilic et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Kalavacherla et al., 2023</xref>). Therefore, complementary biomarkers are urgently needed to improve diagnostic accuracy. Our PW-MR study revealed that genetically plasma MSMB levels were causally associated with PCa risk. Importantly, this aligns with the clinical utility of urinary MSMB: a quadriplex urine panel (MSMB, TRPM8, AMACR, PCA3) improved diagnostic accuracy in PCa patients compared to PSA alone (<xref ref-type="bibr" rid="bib36">Jamaspishvili et al., 2011</xref>). While plasma MSMB reflects systemic risk, urinary MSMB captures localized prostate pathology, together offering complementary insights into PCa biology. In conclusion, systematic integration of proteomic biomarkers identified through causal inference frameworks with PSA-based screening offers a path to resolve the persistent challenges of PCa diagnostic accuracy.</p><p>Emerging evidence implicates metabolic syndrome (MetS), which encompasses a cluster of conditions, including central obesity, dyslipidemia, and hypertension, may be a risk factor of PCa and may also worsen outcomes (<xref ref-type="bibr" rid="bib30">Hernández-Pérez et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Lifshitz et al., 2021</xref>). The significant association between BMI-adjusted WHR and advanced PCa risk suggested that central obesity may play a critical role in the development of PCa (<xref ref-type="bibr" rid="bib22">Genkinger et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Perez-Cornago et al., 2022</xref>). Visceral adiposity may increase risk of advanced forms of PCa through changes in cytokines and growth factors, hormone regulation, and metabolism (<xref ref-type="bibr" rid="bib14">Doyle et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Himbert et al., 2017</xref>). These metabolic perturbations extend beyond obesity itself, intersecting with broader lipid and inflammatory pathways that further modulate PCa risk. For instance, HDL cholesterol, while classically recognized for its cardioprotective roles in reverse cholesterol transport and antioxidant and anti-inflammatory activities (<xref ref-type="bibr" rid="bib60">Rohatgi et al., 2021</xref>), may also antagonize prostate carcinogenesis. Epidemiological and preclinical studies found that HDL may suppress prostate carcinogenesis by reducing oxidative stress and the levels of pro-inflammatory molecules in cancer cells and TME (<xref ref-type="bibr" rid="bib56">Ossoli et al., 2022</xref>; <xref ref-type="bibr" rid="bib62">Ruscica et al., 2018</xref>). However, in obesity, HDL’s antioxidant and anti-inflammatory capacity is impaired due to altered composition and reduced functionality (<xref ref-type="bibr" rid="bib1">Bacchetti et al., 2024</xref>), while adipose-derived ROS and cytokines further amplify oxidative damage (<xref ref-type="bibr" rid="bib2">Balan et al., 2024</xref>). The loss of HDL protection and obesity-driven oxidative stress provides a physiological mechanistic basis for obesity-associated PCa aggressivity. This metabolic-inflammatory axis extends to hypertension, which is another MetS hallmark. Although results from previous studies of the association between hypertension and PCa development remain inconsistent (<xref ref-type="bibr" rid="bib9">Christakoudi et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Liang et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Seretis et al., 2019</xref>), an MR analysis suggested that elevated systolic blood pressure might increase PCa risk through systemic inflammation (<xref ref-type="bibr" rid="bib69">Stikbakke et al., 2022</xref>), a mechanism similar to that of central obesity and HDL dysfunction. Chronic inflammation contributes to a pro-tumorigenic environment by promoting cellular proliferation, DNA damage, and resistance to apoptosis (<xref ref-type="bibr" rid="bib49">Mantovani et al., 2008</xref>). Thus, MetS components likely converge on overlapping pathways to accelerate PCa progression, though the precise relationship between systolic blood pressure and PCa remains unclear. More research is needed to elucidate the exact biological pathways involved and to determine whether managing clinical features of MetS could serve as a preventive strategy for PCa.</p><p>The link between androgenic alopecia (AGA) and PCa risk further implicates androgen metabolism as a central driver, as both conditions are influenced by dihydrotestosterone (DHT) levels. In AGA, DHT binds to androgen receptors (AR) in the dermal papilla cells, causing follicular miniaturization and hair loss (<xref ref-type="bibr" rid="bib74">Urysiak-Czubatka et al., 2014</xref>). Similarly, DHT-driven AR activation in prostate epithelial cells promotes proliferation and inhibits apoptosis, fostering tumorigenesis (<xref ref-type="bibr" rid="bib73">Tong et al., 2022</xref>). However, the link between AGA and PCa may not be solely hormone-dependent. Genetic pleiotropy, where variants in loci such as AR or SRD5A2 influence both balding and prostate carcinogenesis, could partially explain this association (<xref ref-type="bibr" rid="bib27">Hayes et al., 2005</xref>; <xref ref-type="bibr" rid="bib28">Hayes et al., 2007</xref>). Further studies are needed to confirm the causality.</p><p>Overall, our cross-phenotype analysis provided a comprehensive view of the diverse factors associated with PCa and enhanced our understanding of the disease’s multifaceted nature. Future research should focus on elucidating the underlying mechanisms of these associations and exploring their potential for integration into clinical practice.</p></sec><sec id="s3-3"><title>Plasma proteins causal links to prostate cancer</title><p>The PW-MR study supplemented by colocalization analysis identified 193 unique proteins causally associated with PCa, including 10 with robust colocalization evidence. These findings pinpoint both established and novel protein mediators of PCa pathogenesis, offering actionable insights into diagnostic and therapeutic innovation.</p><p>Microseminoprotein-beta (MSMB), the second most abundant prostate-secreted protein after PSA (<xref ref-type="bibr" rid="bib44">Lilja and Abrahamsson, 1988</xref>), has been shown to control prostate cell growth by regulating apoptosis (<xref ref-type="bibr" rid="bib20">Garde et al., 1999</xref>). Unlike PSA, MSMB expression is not directly regulated by androgens. This androgen independence makes it possible for MSMB to be a supplementary biomarker for PSA, particularly in contexts where androgen receptor signaling is dysregulated, such as castration-resistant prostate cancer (CRPC) (<xref ref-type="bibr" rid="bib67">Sjöblom et al., 2016</xref>). Our study found that MSMB demonstrated the strongest protective association, and this finding was validated in prospective studies (<xref ref-type="bibr" rid="bib68">Smith Byrne et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Haiman et al., 2013</xref>), supporting a potential protective role of MSMB in PCa. Some studies reported the level of MSMB in benign prostate tissues or BPH was significantly elevated and decreased or lost in PCa (<xref ref-type="bibr" rid="bib47">Luebke et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Nam et al., 2006</xref>; <xref ref-type="bibr" rid="bib78">Whitaker et al., 2010</xref>); however, others paradoxically observed that the decreased expression of MSMB was both in the tumor (especially in more advanced tumor) and adjacent benign prostate tissue (<xref ref-type="bibr" rid="bib3">Bergström et al., 2018</xref>). This apparent discrepancy may reflect dynamic compensatory regulation during disease progression. In early carcinogenesis, benign epithelia adjacent to low-grade tumors may upregulate MSMB as a protective response to counteract oncogenic stress, whereas advanced tumors drive epigenetic silencing of MSMB, propagating a permissive microenvironment for invasion. Overall, these findings position MSMB as a promising biomarker, which is expected to enhance the diagnostic and prognostic specificity of PCa through integration with PSA.</p><p>SERPINA3 is an inhibitor of serine proteases that was previously found to be upregulated in various types of cancer and its elevation was associated with a worse prognosis (<xref ref-type="bibr" rid="bib13">de Mezer et al., 2023</xref>). Mechanistically, SERPINA3 is regulated by inflammatory cytokines so that its expression is increased in the inflammatory response (<xref ref-type="bibr" rid="bib57">Péré-Brissaud et al., 2015</xref>) and may drive tumor progression. SERPINA3 emerged as a significant risk factor for PCa in our MR analysis, which aligns with several proteomics (<xref ref-type="bibr" rid="bib54">Nguyen et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2022</xref>). The overexpression of SERPINA3 indicates that damage tends to occur in the body contributing to decreased cell adhesion ability and inhibition of apoptosis (<xref ref-type="bibr" rid="bib6">Chelbi et al., 2012</xref>). These alterations may synergistically enhance metastatic potential, as evidenced by a recent study linking SERPINA3 to bone metastasis. A study identified that the enhanced expression of SERPINA3 stimulated the bone environment by promoting osteoblasts and osteoclasts activation, suggesting that it may serve a diagnostic biomarker for PCa with bone metastasis phenotype and survival (<xref ref-type="bibr" rid="bib35">Ito et al., 2023</xref>).</p><p>PRSS3, also named mesotrypsin, is reported to be aberrantly expressed in various types of tumors and participates in the progression and development of cancers. For example, PRSS3 was identified to be downregulated in lung cancer (<xref ref-type="bibr" rid="bib84">Zhou et al., 2023</xref>) but upregulated in pancreatic cancer (<xref ref-type="bibr" rid="bib38">Jiang et al., 2010</xref>; <xref ref-type="bibr" rid="bib80">Xing et al., 2019</xref>), suggesting that it may have different roles depending on the cellular or disease ways. A study demonstrated that PRSS3 was ectopically expressed in metastatic tissues of PCa and identified PRSS3 as a promising therapeutic target for metastatic PCa (<xref ref-type="bibr" rid="bib32">Hockla et al., 2012</xref>). The research of PRSS3 in PCa is relatively limited, and further studies are necessary to fully understand the functions and mechanisms of PRSS3 in human PCa.</p><p>KLK3, which codes for PSA, is a well-known PCa biomarker. While its diagnostic utility is clinically validated, emerging evidences reveal that KLK3 mRNA detection in whole blood has a predictive role in tumor progression and therapeutic resistance, which is expected to become a potential prognostic marker for PCa (<xref ref-type="bibr" rid="bib4">Boerrigter et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Cho et al., 2024</xref>). KLK3’s canonical role as a serine protease involves cleaving extracellular matrix components and activating matrix metalloproteinases to promote tumor invasion and metastasis (<xref ref-type="bibr" rid="bib16">Escaff et al., 2010</xref>; <xref ref-type="bibr" rid="bib51">Moradi et al., 2019</xref>). Additionally, the androgen regulation of KLK3 expression correlated with the androgen receptor signaling pathway, a critical driver of PCa progression, particularly in CRPC (<xref ref-type="bibr" rid="bib45">Lilja et al., 2008</xref>). Despite these insights, the precise biological pathways through which KLK3 contributes to PCa progression remain incompletely understood. Further research is needed to illustrate the direct and indirect effects of KLK3 on PCa cells and TME.</p><p>Despite substantial preclinical efforts identifying numerous promising biomarkers, their translation into routine clinical application remains strikingly limited due to the lack of further validation. Therefore, prospective validation is important and crucial.</p></sec><sec id="s3-4"><title>Biological mechanisms and druggable targets</title><p>Our integrative analysis revealed that the 193 candidate genes identified through MR were significantly enriched in inflammatory/immune pathways (e.g., cytokine–cytokine receptor interaction, JAK-STAT signaling) and cancer-related processes such as apoptosis and cell adhesion. These pathways not only depict the molecular landscape of PCa but also identify viable targets for therapeutic intervention.</p><p>For instance, RRM2B is a DNA repair enzyme targeted by the clinical-stage drug TRIAPINE, and its role in maintaining genomic stability under replicative stress is consistent with the enrichment of the p53 signaling pathway (<xref ref-type="bibr" rid="bib15">Elfar et al., 2024</xref>). Similarly, the cell adhesion pathways are central to metastatic dissemination. As a member of the Thy-1/Ly-6 family involved in cell adhesion and metastasis, PSCA’s overexpression in high-grade PCa and metastatic lesions underscores the therapeutic potential of PSCA inhibitors in targeting tumor-stroma crosstalk to prevent metastatic spread (<xref ref-type="bibr" rid="bib53">Nayerpour Dizaj et al., 2024</xref>). Furthermore, HSPB1, a molecular chaperone implicated in apoptosis evasion and chemotherapy resistance (<xref ref-type="bibr" rid="bib21">Garrido et al., 2006</xref>; <xref ref-type="bibr" rid="bib25">Hadaschik et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Kamada et al., 2007</xref>), aligns with the observed enrichment of survival pathways in aggressive PCa (<xref ref-type="bibr" rid="bib66">Shiota et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Vasiljević et al., 2013</xref>). The antisense oligonucleotide APATORSEN, which silences HSPB1, restores chemosensitivity by reactivating apoptotic signaling, offering a strategy for therapeutic resistance against CRPC (<xref ref-type="bibr" rid="bib41">Le et al., 2023</xref>). Beyond these prioritized targets, the druggability analysis uncovered broader therapeutic potential. Proteins like RET (enriched in JAK-STAT signaling) and FGFR3 (linked to pathways in cancer) are already targeted by approved therapies in other malignancies, suggesting rapid repurposing potential for PCa. In conclusion, bridging pathway enrichment with druggability data transforms genetic associations into therapeutic hypotheses.</p></sec><sec id="s3-5"><title>Study strengths and limitations</title><p>This study possessed several strengths, including the use of the largest collection of plasma protein data (covering more than 4800 proteins), large sample sizes of GWAS, a mutual validation across two independent outcome datasets, and the use of colocalization analysis to support the MR results. Additionally, our assessment of the human blood proteome relied on two technologies (SOMAmer and Olink), which were valuable for identifying plasma proteins associated with disease traits such as PCa.</p><p>Some limitations of our analysis should be acknowledged. Firstly, this investigation was only confined to Europeans, restricting the applicability of our findings to other populations. It is crucial for future studies to identify risk proteins in more diverse populations, especially African ancestry who face a higher risk of PCa. Secondly, our study concentrated on the proteins available in the MR analysis, which likely led to the omission of other potential therapeutic targets. Thirdly, we utilized proteomic data from Icelanders whose genetic backgrounds may differ from other European populations, which might introduce bias. Lastly, our analysis relied exclusively on publicly available GWAS summary statistics from openGWAS and FinnGen, which did not provide individual-level data on covariates, resulting in no direct assessment of demographic or clinical differences between cases and controls. However, this potential bias might be minimal, as we found that 20 proteins showing significance (<italic>P</italic>&lt;0.05) in both the deCODE and UKB-PPP studies had consistent associations with PCa.</p><p>In conclusion, we conducted a large-scale PW-MR study using the MR and colocalization analysis to investigate the genetic associations of up to 3722 unique proteins with PCa. We revealed the complex genetic architecture of PCa and identified many new plasma proteins with strong causal associations to PCa. These findings highlighted the potential biomarkers for early detection and therapeutic targets, providing a foundation for future research and potential clinical applications.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study design</title><p>An overview of the analytical framework is depicted in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Briefly, the proteome-wide MR study was designed to assess the causal effects of human plasma proteins on PCa risk. We integrated genetic instruments for 3722 plasma proteins from two large-scale studies with summary-level genome-wide association data from a meta-analysis of 94,397 cases and 192,372 controls. The analytical workflow comprised protein-specific MR estimates, sensitivity, and colocalization analyses to verify robustness, followed by cross-phenotype, biological pathway, and druggability evaluations of the significant findings.</p></sec><sec id="s4-2"><title>Data sources for plasma proteins</title><p>We selected <italic>cis</italic>-SNPs associated with plasma proteins as instrumental variables from two large-scale GWASs in the deCODE Genetics (<xref ref-type="bibr" rid="bib17">Ferkingstad et al., 2021</xref>) and UKB-PPP (<xref ref-type="bibr" rid="bib70">Sun et al., 2023</xref>). <italic>cis</italic>-SNPs were defined as SNPs within a vicinity of ±1 Mb around the gene encoding the protein. From these SNPs, only those with a minor allele frequency of ≥1% that were genome-wide significance (<italic>P</italic>&lt;5 × 10<sup>–8</sup>) and considered independent (linkage disequilibrium r<sup>2</sup> &lt;0.1 in 1000G) were retained. deCODE Genetics conducted proteomic profiling on blood plasma samples from 35,559 Icelanders using the SomaScan platform and collected data on 4907 aptamers (<xref ref-type="bibr" rid="bib17">Ferkingstad et al., 2021</xref>). For the two-sample MR analysis, we selected <italic>cis</italic>-SNPs as instrumental variables for 1778 proteins. Likewise, <italic>cis</italic>-SNPs for 1944 plasma proteins were obtained from the UKB-PPP where 2940 proteins were measured among 54,219 Europeans using the Olink platform (<xref ref-type="bibr" rid="bib70">Sun et al., 2023</xref>). The proteins with positive MR results were included in the colocalization analysis.</p></sec><sec id="s4-3"><title>Data sources for prostate cancer</title><p>GWAS summary statistics for PCa were obtained from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium (<xref ref-type="bibr" rid="bib64">Schumacher et al., 2019</xref>) and FinnGen study. The PRACTICAL consortium included 79,198 cases and 61,106 controls. We used the data on PCa from the FinnGen study R10 in this analysis, which comprised 15,199 cases and 131,266 controls. All participants of these two cohorts were of European ancestry. In the MR analysis, we treated the PRACTICAL consortium as the discovery study and the FinnGen R10 study as the replication. To increase the effectiveness, we performed a fixed-effect GWAS meta-analysis of the two GWASs using the METAL package. The quantile–quantile plot was generated using the ‘qqman’ package in R software (4.3.3). The R package ‘gassocplot’ was used to plot regional association plots for the top SNP at each of the genome-wide significant loci identified.</p></sec><sec id="s4-4"><title>Cross-phenotype analysis</title><p>Through the interactive cross-phenotype analysis of GWAS database (iCPAGdb) (<xref ref-type="bibr" rid="bib76">Wang et al., 2020</xref>), a new platform for cross-phenotype analysis, we explored the genetic correlation between PCa and other traits. We analyzed the genetic correlations between PCa and 3793 traits using data from the National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS catalog (<xref ref-type="bibr" rid="bib76">Wang et al., 2020</xref>). Through the use of ancestry LD-specific association data, iCPAGdb performs cross-phenotype enrichment analyses. iCPAGdb reveals signals of pairwise traits and shared signals by analyzing traits associations with LD proxy SNPs. The output data will show results from Fisher’s exact test with adjustment for 5% FDR and also Bonferroni’s, Jaccard’s, Sorensen’s, and Chao–Sorensen similarity indexes.</p></sec><sec id="s4-5"><title>MR analysis</title><p>We conducted a MR analysis with plasma proteins as the exposure variable and PC as the outcome variable. We utilized the R package ‘TwoSampleMR’ in R software (4.3.3) for the MR analysis. When only one SNP was available for a particular protein, we applied the Wald ratio test. IVW was used as the main analysis method for two or more SNPs available. Considering multiple testing, we employed the 5% FDR method for <italic>P</italic>-value correction. <italic>P</italic>&lt;0.05 was considered statistically significant. MR-Egger and weighted median methods were used as supplementary analysis methods. Cochran’s Q statistic test using the MR-Egger method was used to determine the heterogeneity between the genetic variants. We also performed MR-Egger regression intercept to detect and adjust the directional horizontal pleiotropy (<xref ref-type="bibr" rid="bib29">Hemani et al., 2018</xref>). <italic>P</italic>&lt;0.05 was considered the presence of directional pleiotropy and thus removed from the further analyses.</p></sec><sec id="s4-6"><title>Colocalization analysis</title><p>The ‘coloc’ package was used to perform Bayesian colocalization analysis to investigate if the associations between plasma proteins and PCa were driven by linkage disequilibrium (LD) (<xref ref-type="bibr" rid="bib23">Giambartolomei et al., 2014</xref>). For proteins with positive MR results, the Bayesian method assessed the support for the following five exclusive hypotheses: (1) no association with either trait; (2) association with trait 1 only; (3) association with trait 2 only; (4) both traits are associated, but distinct causal variants were for two traits; and (5) both traits are associated, and the same shares causal variant for both traits (<xref ref-type="bibr" rid="bib19">Foley et al., 2021</xref>). The posterior probability is provided for each hypothesis (H0, H1, H2, H3, and H4). In this analysis, we set prior probabilities of the SNP being associated with trait 1 only (p1) at 1×10<sup>−4</sup>; the probability of the SNP being associated with trait 2 only (p2) at 1×10<sup>−4</sup>; and the probability of the SNP being associated with both traits (p12) at 1×10<sup>−5</sup>. Two signals were considered to have strong evidence of colocalization if the posterior probability for shared causal variants (PH4) was ≥0.8. The analysis was performed in R software (4.3.3).</p></sec><sec id="s4-7"><title>Biological pathway analysis</title><p>The GENE2FUNC tool in FUMA (<xref ref-type="bibr" rid="bib77">Watanabe et al., 2017</xref>) web application programming interface version 1.5.2 was used to investigate functional annotation and enrichment analysis of the genes coding for the 193 unique proteins identified by the PW-MR approach. This analysis involved calculating the log2 fold-change expression for each gene across 54 tissue types from the GTEx (genotype–tissue expression) database. We conducted gene enrichment analysis to identify overrepresented biological processes using the Gene Ontology (GO) database, which helped determine the biological processes most relevant to the genes identified. To investigate the involvement of the identified genes in functional and signaling pathways, we used the KEGG pathway database. Enrichment results were considered significant if they passed a 5% FDR <italic>P</italic>-value threshold. Additionally, only enrichments involving at least two overlapping genes with the gene sets were considered to ensure robustness and biological relevance.</p></sec><sec id="s4-8"><title>Druggability evaluation</title><p>The analysis of drug targets for the significant proteins identified in the MR analysis was conducted using data from OpenTargets (<xref ref-type="bibr" rid="bib55">Ochoa et al., 2023</xref>) (v.22.11), which is publicly accessible. We selected all drugs for which there was evidence for an association with the protein of interest.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Software, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Supervision, Funding acquisition, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary tables for the MR study on plasma proteins and PCa.</title><p>(A) Results of genome-wide significant hits and assessment of heterogeneity in meta-analysis. (B) Cross-phenotype associations with PC from iCPAGdb. (C) Full results of the proteome-wide MR in deCODE including coloc and sensitivity analyses. (D) Full results of the proteome-wide MR in UKB_PPP including coloc and sensitivity analyses. (E) Results comparison between proteins significant in either dataset or in both. (F) OpenTargets drug targets.</p></caption><media xlink:href="elife-101584-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-101584-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data used in this secondary analysis are publicly available. The GWAS summary statistics of blood pQTLs from deCODE can be found at <ext-link ext-link-type="uri" xlink:href="https://www.decode.com/summarydata/">https://www.decode.com/summarydata/</ext-link>, and those of the UKB-PPP can be found at <ext-link ext-link-type="uri" xlink:href="https://www.ukbiobank.ac.uk/">https://www.ukbiobank.ac.uk/</ext-link>. Summary statistics of PCa from the PRACTICAL consortium can be obtained from OpenGWAS (<ext-link ext-link-type="uri" xlink:href="https://gwas.mrcieu.ac.uk/">https://gwas.mrcieu.ac.uk/</ext-link>), and those of the FinnGen study can be obtained from <ext-link ext-link-type="uri" xlink:href="https://r10.finngen.fi/">https://r10.finngen.fi/</ext-link>. The OpenTargets data were downloaded directly from the OpenTargets website (<ext-link ext-link-type="uri" xlink:href="https://platform.opentargets.org/downloads/data">https://platform.opentargets.org/downloads/data</ext-link>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank all the participants and investigators of the studies (PRACTICAL, FinnGen, deCODE, UKB-PPP) for providing the invaluable data used in this research. Their commitment and effort have been essential for the success of this study. Furthermore, special thanks to our colleagues and collaborators for their insightful discussions and feedback throughout the research process. This research was funded by Beijing Municipal Natural Science Foundation (grant no. JQ24059, no. L234038, no. L248076), and National Natural Science Foundation of China (grant no. 82274015).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacchetti</surname><given-names>T</given-names></name><name><surname>Morresi</surname><given-names>C</given-names></name><name><surname>Simonetti</surname><given-names>O</given-names></name><name><surname>Ferretti</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Effect of diet on HDL in obesity</article-title><source>Molecules</source><volume>29</volume><elocation-id>5955</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29245955</pub-id><pub-id pub-id-type="pmid">39770044</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balan</surname><given-names>AI</given-names></name><name><surname>Halațiu</surname><given-names>VB</given-names></name><name><surname>Scridon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Oxidative stress, inflammation, and mitochondrial dysfunction: a link between obesity and atrial fibrillation</article-title><source>Antioxidants</source><volume>13</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.3390/antiox13010117</pub-id><pub-id pub-id-type="pmid">38247541</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergström</surname><given-names>SH</given-names></name><name><surname>Järemo</surname><given-names>H</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Adamo</surname><given-names>HH</given-names></name><name><surname>Bergh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness</article-title><source>The Prostate</source><volume>78</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/pros.23466</pub-id><pub-id pub-id-type="pmid">29250809</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boerrigter</surname><given-names>E</given-names></name><name><surname>Benoist</surname><given-names>GE</given-names></name><name><surname>van Oort</surname><given-names>IM</given-names></name><name><surname>Verhaegh</surname><given-names>GW</given-names></name><name><surname>van Hooij</surname><given-names>O</given-names></name><name><surname>Groen</surname><given-names>L</given-names></name><name><surname>Smit</surname><given-names>F</given-names></name><name><surname>Oving</surname><given-names>IM</given-names></name><name><surname>de Mol</surname><given-names>P</given-names></name><name><surname>Smilde</surname><given-names>TJ</given-names></name><name><surname>Somford</surname><given-names>DM</given-names></name><name><surname>Mehra</surname><given-names>N</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name><name><surname>van Erp</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment</article-title><source>Molecular Oncology</source><volume>15</volume><fpage>2453</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12933</pub-id><pub-id pub-id-type="pmid">33650292</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Nimptsch</surname><given-names>K</given-names></name><name><surname>Shui</surname><given-names>IM</given-names></name><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Pollak</surname><given-names>MN</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer</article-title><source>International Journal of Cancer</source><volume>136</volume><fpage>2418</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.1002/ijc.29295</pub-id><pub-id pub-id-type="pmid">25348852</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chelbi</surname><given-names>ST</given-names></name><name><surname>Wilson</surname><given-names>ML</given-names></name><name><surname>Veillard</surname><given-names>AC</given-names></name><name><surname>Ingles</surname><given-names>SA</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Mondon</surname><given-names>F</given-names></name><name><surname>Vaiman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetic and epigenetic mechanisms collaborate to control</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>1968</fpage><lpage>1978</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds006</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>LT</given-names></name><name><surname>Wang</surname><given-names>ML</given-names></name><name><surname>Laurent</surname><given-names>B</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Pan</surname><given-names>CM</given-names></name><name><surname>Jiang</surname><given-names>WR</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Ma</surname><given-names>HI</given-names></name><name><surname>Chen</surname><given-names>YW</given-names></name><name><surname>Huang</surname><given-names>PI</given-names></name><name><surname>Chiou</surname><given-names>A</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Musashi-1 enhances glioblastoma cell migration and cytoskeletal dynamics through translational inhibition of tensin3</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>8710</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-09504-7</pub-id><pub-id pub-id-type="pmid">28821879</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Byun</surname><given-names>S-S</given-names></name><name><surname>Son</surname><given-names>N-H</given-names></name><name><surname>Chung</surname><given-names>JI</given-names></name><name><surname>Seo</surname><given-names>WI</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Morgan</surname><given-names>TM</given-names></name><name><surname>Han</surname><given-names>K-H</given-names></name><name><surname>Chung</surname><given-names>J-S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in different stages of prostate cancer</article-title><source>Clinical Cancer Research</source><volume>30</volume><fpage>1788</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-3083</pub-id><pub-id pub-id-type="pmid">38587547</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christakoudi</surname><given-names>S</given-names></name><name><surname>Kakourou</surname><given-names>A</given-names></name><name><surname>Markozannes</surname><given-names>G</given-names></name><name><surname>Tzoulaki</surname><given-names>I</given-names></name><name><surname>Weiderpass</surname><given-names>E</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Gunter</surname><given-names>M</given-names></name><name><surname>Dahm</surname><given-names>CC</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Olsen</surname><given-names>A</given-names></name><name><surname>Tjønneland</surname><given-names>A</given-names></name><name><surname>Boutron-Ruault</surname><given-names>M-C</given-names></name><name><surname>Madika</surname><given-names>A-L</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Katzke</surname><given-names>V</given-names></name><name><surname>Kühn</surname><given-names>T</given-names></name><name><surname>Bergmann</surname><given-names>MM</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Karakatsani</surname><given-names>A</given-names></name><name><surname>Martimianaki</surname><given-names>G</given-names></name><name><surname>Thriskos</surname><given-names>P</given-names></name><name><surname>Masala</surname><given-names>G</given-names></name><name><surname>Sieri</surname><given-names>S</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Ricceri</surname><given-names>F</given-names></name><name><surname>Agudo</surname><given-names>A</given-names></name><name><surname>Redondo-Sánchez</surname><given-names>D</given-names></name><name><surname>Colorado-Yohar</surname><given-names>SM</given-names></name><name><surname>Mokoroa</surname><given-names>O</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Stocks</surname><given-names>T</given-names></name><name><surname>Häggström</surname><given-names>C</given-names></name><name><surname>Harlid</surname><given-names>S</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>B</given-names></name><name><surname>van Gils</surname><given-names>CH</given-names></name><name><surname>Vermeulen</surname><given-names>RCH</given-names></name><name><surname>Khaw</surname><given-names>K-T</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Tong</surname><given-names>TYN</given-names></name><name><surname>Freisling</surname><given-names>H</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>H</given-names></name><name><surname>Aune</surname><given-names>D</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Trichopoulos</surname><given-names>D</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Tsilidis</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition</article-title><source>International Journal of Cancer</source><volume>146</volume><fpage>2680</fpage><lpage>2693</lpage><pub-id pub-id-type="doi">10.1002/ijc.32576</pub-id><pub-id pub-id-type="pmid">31319002</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Chatterjee</surname><given-names>B</given-names></name><name><surname>Lozito</surname><given-names>TP</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Francis</surname><given-names>RJ</given-names></name><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>Swanhart</surname><given-names>LM</given-names></name><name><surname>Sanker</surname><given-names>S</given-names></name><name><surname>Francis</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>San Agustin</surname><given-names>JT</given-names></name><name><surname>Puligilla</surname><given-names>C</given-names></name><name><surname>Chatterjee</surname><given-names>T</given-names></name><name><surname>Tansey</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Kelley</surname><given-names>MW</given-names></name><name><surname>Spiliotis</surname><given-names>ET</given-names></name><name><surname>Kwiatkowski</surname><given-names>AV</given-names></name><name><surname>Tuan</surname><given-names>R</given-names></name><name><surname>Pazour</surname><given-names>GJ</given-names></name><name><surname>Hukriede</surname><given-names>NA</given-names></name><name><surname>Lo</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Wdpcp, a PCP protein required for ciliogenesis, regulates directional cell migration and cell polarity by direct modulation of the actin cytoskeleton</article-title><source>PLOS Biology</source><volume>11</volume><elocation-id>e1001720</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001720</pub-id><pub-id pub-id-type="pmid">24302887</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>NM</given-names></name><name><surname>Holmes</surname><given-names>MV</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians</article-title><source>BMJ</source><volume>362</volume><elocation-id>k601</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.k601</pub-id><pub-id pub-id-type="pmid">30002074</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deichaite</surname><given-names>I</given-names></name><name><surname>Sears</surname><given-names>TJ</given-names></name><name><surname>Sutton</surname><given-names>L</given-names></name><name><surname>Rebibo</surname><given-names>D</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Nelson</surname><given-names>T</given-names></name><name><surname>Rose</surname><given-names>B</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Asimakopoulos</surname><given-names>F</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer</article-title><source>Journal of Translational Medicine</source><volume>20</volume><elocation-id>527</elocation-id><pub-id pub-id-type="doi">10.1186/s12967-022-03731-x</pub-id><pub-id pub-id-type="pmid">36371231</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Mezer</surname><given-names>M</given-names></name><name><surname>Rogaliński</surname><given-names>J</given-names></name><name><surname>Przewoźny</surname><given-names>S</given-names></name><name><surname>Chojnicki</surname><given-names>M</given-names></name><name><surname>Niepolski</surname><given-names>L</given-names></name><name><surname>Sobieska</surname><given-names>M</given-names></name><name><surname>Przystańska</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SERPINA3: stimulator or inhibitor of pathological changes</article-title><source>Biomedicines</source><volume>11</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines11010156</pub-id><pub-id pub-id-type="pmid">36672665</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>SL</given-names></name><name><surname>Donohoe</surname><given-names>CL</given-names></name><name><surname>Lysaght</surname><given-names>J</given-names></name><name><surname>Reynolds</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Visceral obesity, metabolic syndrome, insulin resistance and cancer</article-title><source>The Proceedings of the Nutrition Society</source><volume>71</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1017/S002966511100320X</pub-id><pub-id pub-id-type="pmid">22051112</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elfar</surname><given-names>GA</given-names></name><name><surname>Aning</surname><given-names>O</given-names></name><name><surname>Ngai</surname><given-names>TW</given-names></name><name><surname>Yeo</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>JWK</given-names></name><name><surname>Sim</surname><given-names>SH</given-names></name><name><surname>Goh</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Phua</surname><given-names>CZJ</given-names></name><name><surname>Yeo</surname><given-names>JZZ</given-names></name><name><surname>Mak</surname><given-names>SY</given-names></name><name><surname>Goh</surname><given-names>BKP</given-names></name><name><surname>Chow</surname><given-names>PK-H</given-names></name><name><surname>Tam</surname><given-names>WL</given-names></name><name><surname>Ho</surname><given-names>YS</given-names></name><name><surname>Cheok</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>p53-dependent crosstalk between DNA replication integrity and redox metabolism mediated through a NRF2-PARP1 axis</article-title><source>Nucleic Acids Research</source><volume>52</volume><fpage>12351</fpage><lpage>12377</lpage><pub-id pub-id-type="doi">10.1093/nar/gkae811</pub-id><pub-id pub-id-type="pmid">39315696</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escaff</surname><given-names>S</given-names></name><name><surname>Fernández</surname><given-names>JM</given-names></name><name><surname>González</surname><given-names>LO</given-names></name><name><surname>Suárez</surname><given-names>A</given-names></name><name><surname>González-Reyes</surname><given-names>S</given-names></name><name><surname>González</surname><given-names>JM</given-names></name><name><surname>Vizoso</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Study of matrix metalloproteinases and their inhibitors in prostate cancer</article-title><source>British Journal of Cancer</source><volume>102</volume><fpage>922</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605569</pub-id><pub-id pub-id-type="pmid">20160732</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferkingstad</surname><given-names>E</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Atlason</surname><given-names>BA</given-names></name><name><surname>Sveinbjornsson</surname><given-names>G</given-names></name><name><surname>Magnusson</surname><given-names>MI</given-names></name><name><surname>Styrmisdottir</surname><given-names>EL</given-names></name><name><surname>Gunnarsdottir</surname><given-names>K</given-names></name><name><surname>Helgason</surname><given-names>A</given-names></name><name><surname>Oddsson</surname><given-names>A</given-names></name><name><surname>Halldorsson</surname><given-names>BV</given-names></name><name><surname>Jensson</surname><given-names>BO</given-names></name><name><surname>Zink</surname><given-names>F</given-names></name><name><surname>Halldorsson</surname><given-names>GH</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Arnadottir</surname><given-names>GA</given-names></name><name><surname>Katrinardottir</surname><given-names>H</given-names></name><name><surname>Juliusson</surname><given-names>K</given-names></name><name><surname>Magnusson</surname><given-names>MK</given-names></name><name><surname>Magnusson</surname><given-names>OT</given-names></name><name><surname>Fridriksdottir</surname><given-names>R</given-names></name><name><surname>Saevarsdottir</surname><given-names>S</given-names></name><name><surname>Gudjonsson</surname><given-names>SA</given-names></name><name><surname>Stacey</surname><given-names>SN</given-names></name><name><surname>Rognvaldsson</surname><given-names>S</given-names></name><name><surname>Eiriksdottir</surname><given-names>T</given-names></name><name><surname>Olafsdottir</surname><given-names>TA</given-names></name><name><surname>Steinthorsdottir</surname><given-names>V</given-names></name><name><surname>Tragante</surname><given-names>V</given-names></name><name><surname>Ulfarsson</surname><given-names>MO</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Jonsdottir</surname><given-names>I</given-names></name><name><surname>Holm</surname><given-names>H</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Saemundsdottir</surname><given-names>J</given-names></name><name><surname>Norddahl</surname><given-names>GL</given-names></name><name><surname>Lund</surname><given-names>SH</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Large-scale integration of the plasma proteome with genetics and disease</article-title><source>Nature Genetics</source><volume>53</volume><fpage>1712</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00978-w</pub-id><pub-id pub-id-type="pmid">34857953</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ervik</surname><given-names>M</given-names></name><name><surname>Lam</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Colombet</surname><given-names>M</given-names></name><name><surname>Mery</surname><given-names>L</given-names></name><name><surname>Piñeros</surname><given-names>M</given-names></name><name><surname>Znaor</surname><given-names>A</given-names></name><name><surname>Piñeros</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Global cancer observatory: cancer today</article-title><ext-link ext-link-type="uri" xlink:href="https://gco.iarc.who.int/today">https://gco.iarc.who.int/today</ext-link><date-in-citation iso-8601-date="2024-02-01">February 1, 2024</date-in-citation></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>CN</given-names></name><name><surname>Staley</surname><given-names>JR</given-names></name><name><surname>Breen</surname><given-names>PG</given-names></name><name><surname>Sun</surname><given-names>BB</given-names></name><name><surname>Kirk</surname><given-names>PDW</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Howson</surname><given-names>JMM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>764</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20885-8</pub-id><pub-id pub-id-type="pmid">33536417</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garde</surname><given-names>SV</given-names></name><name><surname>Basrur</surname><given-names>VS</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Finkelman</surname><given-names>MA</given-names></name><name><surname>Krishan</surname><given-names>A</given-names></name><name><surname>Wellham</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis</article-title><source>The Prostate</source><volume>38</volume><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1002/(sici)1097-0045(19990201)38:23.0.Co;2-g</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>C</given-names></name><name><surname>Brunet</surname><given-names>M</given-names></name><name><surname>Didelot</surname><given-names>C</given-names></name><name><surname>Zermati</surname><given-names>Y</given-names></name><name><surname>Schmitt</surname><given-names>E</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Heat shock proteins 27 and 70</article-title><source>Cell Cycle</source><volume>5</volume><fpage>2592</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.4161/cc.5.22.3448</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genkinger</surname><given-names>JM</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>A</given-names></name><name><surname>van den Brandt</surname><given-names>PA</given-names></name><name><surname>Burke</surname><given-names>KA</given-names></name><name><surname>Cook</surname><given-names>MB</given-names></name><name><surname>Gapstur</surname><given-names>SM</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Goodman</surname><given-names>GG</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Håkansson</surname><given-names>N</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Männistö</surname><given-names>S</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Liao</surname><given-names>LM</given-names></name><name><surname>MacInnis</surname><given-names>RJ</given-names></name><name><surname>Neuhouser</surname><given-names>ML</given-names></name><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>Sawada</surname><given-names>N</given-names></name><name><surname>Schenk</surname><given-names>JM</given-names></name><name><surname>Stevens</surname><given-names>VL</given-names></name><name><surname>Travis</surname><given-names>RC</given-names></name><name><surname>Tsugane</surname><given-names>S</given-names></name><name><surname>Visvanathan</surname><given-names>K</given-names></name><name><surname>Wilkens</surname><given-names>LR</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><name><surname>Smith-Warner</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer</article-title><source>Annals of Oncology</source><volume>31</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2019.09.007</pub-id><pub-id pub-id-type="pmid">31912782</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giambartolomei</surname><given-names>C</given-names></name><name><surname>Vukcevic</surname><given-names>D</given-names></name><name><surname>Schadt</surname><given-names>EE</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Wallace</surname><given-names>C</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bayesian test for colocalisation between pairs of genetic association studies using summary statistics</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004383</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmid">24830394</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Sigurdsson</surname><given-names>JK</given-names></name><name><surname>Stefansdottir</surname><given-names>L</given-names></name><name><surname>Agnarsson</surname><given-names>BA</given-names></name><name><surname>Isaksson</surname><given-names>HJ</given-names></name><name><surname>Stefansson</surname><given-names>OA</given-names></name><name><surname>Gudjonsson</surname><given-names>SA</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Frigge</surname><given-names>ML</given-names></name><name><surname>Stacey</surname><given-names>SN</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Halldorsson</surname><given-names>GH</given-names></name><name><surname>Tragante</surname><given-names>V</given-names></name><name><surname>Holm</surname><given-names>H</given-names></name><name><surname>Eyjolfsson</surname><given-names>GI</given-names></name><name><surname>Sigurdardottir</surname><given-names>O</given-names></name><name><surname>Olafsson</surname><given-names>I</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Jonsson</surname><given-names>E</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name><name><surname>Hilmarsson</surname><given-names>R</given-names></name><name><surname>Asselbergs</surname><given-names>FW</given-names></name><name><surname>Geirsson</surname><given-names>G</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4568</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06920-9</pub-id><pub-id pub-id-type="pmid">30410027</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadaschik</surname><given-names>BA</given-names></name><name><surname>Jackson</surname><given-names>J</given-names></name><name><surname>Fazli</surname><given-names>L</given-names></name><name><surname>Zoubeidi</surname><given-names>A</given-names></name><name><surname>Burt</surname><given-names>HM</given-names></name><name><surname>Gleave</surname><given-names>ME</given-names></name><name><surname>So</surname><given-names>AI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer</article-title><source>BJU International</source><volume>102</volume><fpage>610</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.07669.x</pub-id><pub-id pub-id-type="pmid">18384625</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Vickers</surname><given-names>AJ</given-names></name><name><surname>Wilkens</surname><given-names>LR</given-names></name><name><surname>Braun</surname><given-names>K</given-names></name><name><surname>Valtonen-André</surname><given-names>C</given-names></name><name><surname>Peltola</surname><given-names>M</given-names></name><name><surname>Pettersson</surname><given-names>K</given-names></name><name><surname>Waters</surname><given-names>KM</given-names></name><name><surname>Marchand</surname><given-names>LL</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Lilja</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations</article-title><source>Journal of the National Cancer Institute</source><volume>105</volume><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs486</pub-id><pub-id pub-id-type="pmid">23213189</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>VM</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Eggleton</surname><given-names>SA</given-names></name><name><surname>Padilla</surname><given-names>EJD</given-names></name><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The E211 G&gt;A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>14</volume><fpage>993</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-04-0778</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>VM</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Padilla</surname><given-names>EJD</given-names></name><name><surname>Morris</surname><given-names>HA</given-names></name><name><surname>Tilley</surname><given-names>WD</given-names></name><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia</article-title><source>International Journal of Cancer</source><volume>120</volume><fpage>776</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1002/ijc.22408</pub-id><pub-id pub-id-type="pmid">17136762</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluating the potential role of pleiotropy in Mendelian randomization studies</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>R195</fpage><lpage>R208</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy163</pub-id><pub-id pub-id-type="pmid">29771313</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Pérez</surname><given-names>JG</given-names></name><name><surname>Torres-Sánchez</surname><given-names>L</given-names></name><name><surname>Hernández-Alcaráz</surname><given-names>C</given-names></name><name><surname>López-Carrillo</surname><given-names>L</given-names></name><name><surname>Rodríguez-Covarrubias</surname><given-names>F</given-names></name><name><surname>Vázquez-Salas</surname><given-names>RA</given-names></name><name><surname>Galván-Portillo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Metabolic syndrome and prostate cancer risk: a population case-control study</article-title><source>Archives of Medical Research</source><volume>53</volume><fpage>594</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2022.07.003</pub-id><pub-id pub-id-type="pmid">35909002</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himbert</surname><given-names>C</given-names></name><name><surname>Delphan</surname><given-names>M</given-names></name><name><surname>Scherer</surname><given-names>D</given-names></name><name><surname>Bowers</surname><given-names>LW</given-names></name><name><surname>Hursting</surname><given-names>S</given-names></name><name><surname>Ulrich</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Signals from the Adipose Microenvironment and the Obesity-Cancer Link-A systematic review</article-title><source>Cancer Prevention Research</source><volume>10</volume><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-16-0322</pub-id><pub-id pub-id-type="pmid">28864539</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockla</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name><name><surname>Salameh</surname><given-names>MA</given-names></name><name><surname>Copland</surname><given-names>JA</given-names></name><name><surname>Radisky</surname><given-names>DC</given-names></name><name><surname>Radisky</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer</article-title><source>Molecular Cancer Research</source><volume>10</volume><fpage>1555</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-12-0314</pub-id><pub-id pub-id-type="pmid">23258495</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname><given-names>AC</given-names></name><name><surname>Mlodzik</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>From instruction to output: Wnt/PCP signaling in development and cancer</article-title><source>Current Opinion in Cell Biology</source><volume>51</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2017.12.005</pub-id><pub-id pub-id-type="pmid">29289896</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilic</surname><given-names>D</given-names></name><name><surname>Djulbegovic</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Hwang</surname><given-names>EC</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Cleves</surname><given-names>A</given-names></name><name><surname>Agoritsas</surname><given-names>T</given-names></name><name><surname>Dahm</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis</article-title><source>BMJ</source><volume>362</volume><elocation-id>k3519</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.k3519</pub-id><pub-id pub-id-type="pmid">30185521</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>J</given-names></name><name><surname>Urabe</surname><given-names>F</given-names></name><name><surname>Shimasaki</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>E</given-names></name><name><surname>Matui</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Egawa</surname><given-names>S</given-names></name><name><surname>Ochiya</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer</article-title><source>Molecular Oncology</source><volume>17</volume><fpage>2147</fpage><lpage>2167</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.13484</pub-id><pub-id pub-id-type="pmid">37408474</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamaspishvili</surname><given-names>T</given-names></name><name><surname>Kral</surname><given-names>M</given-names></name><name><surname>Khomeriki</surname><given-names>I</given-names></name><name><surname>Vyhnankova</surname><given-names>V</given-names></name><name><surname>Mgebrishvili</surname><given-names>G</given-names></name><name><surname>Student</surname><given-names>V</given-names></name><name><surname>Kolar</surname><given-names>Z</given-names></name><name><surname>Bouchal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Quadriplex model enhances urine-based detection of prostate cancer</article-title><source>Prostate Cancer and Prostatic Diseases</source><volume>14</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/pcan.2011.32</pub-id><pub-id pub-id-type="pmid">21788966</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>ND</given-names></name><name><surname>Tannock</surname><given-names>I</given-names></name><name><surname>N’Dow</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Gillessen</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>SA</given-names></name><name><surname>Trujillo</surname><given-names>B</given-names></name><name><surname>Al-Lazikani</surname><given-names>B</given-names></name><name><surname>Attard</surname><given-names>G</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Compérat</surname><given-names>E</given-names></name><name><surname>Eeles</surname><given-names>R</given-names></name><name><surname>Fatiregun</surname><given-names>O</given-names></name><name><surname>Grist</surname><given-names>E</given-names></name><name><surname>Halabi</surname><given-names>S</given-names></name><name><surname>Haran</surname><given-names>Á</given-names></name><name><surname>Herchenhorn</surname><given-names>D</given-names></name><name><surname>Hofman</surname><given-names>MS</given-names></name><name><surname>Jalloh</surname><given-names>M</given-names></name><name><surname>Loeb</surname><given-names>S</given-names></name><name><surname>MacNair</surname><given-names>A</given-names></name><name><surname>Mahal</surname><given-names>B</given-names></name><name><surname>Mendes</surname><given-names>L</given-names></name><name><surname>Moghul</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Morgans</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Murthy</surname><given-names>V</given-names></name><name><surname>Nguyen</surname><given-names>PL</given-names></name><name><surname>Padhani</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Rush</surname><given-names>H</given-names></name><name><surname>Sculpher</surname><given-names>M</given-names></name><name><surname>Soule</surname><given-names>H</given-names></name><name><surname>Sydes</surname><given-names>MR</given-names></name><name><surname>Tilki</surname><given-names>D</given-names></name><name><surname>Tunariu</surname><given-names>N</given-names></name><name><surname>Villanti</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>L-P</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The Lancet Commission on prostate cancer: planning for the surge in cases</article-title><source>Lancet</source><volume>403</volume><fpage>1683</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)00651-2</pub-id><pub-id pub-id-type="pmid">38583453</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Bhakta</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Zang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>HH</given-names></name><name><surname>Hiley</surname><given-names>C</given-names></name><name><surname>Crnogorac-Jurcevic</surname><given-names>T</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PRSS3 promotes tumour growth and metastasis of human pancreatic cancer</article-title><source>Gut</source><volume>59</volume><fpage>1535</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.200105</pub-id><pub-id pub-id-type="pmid">20947888</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalavacherla</surname><given-names>S</given-names></name><name><surname>Riviere</surname><given-names>P</given-names></name><name><surname>Javier-DesLoges</surname><given-names>J</given-names></name><name><surname>Banegas</surname><given-names>MP</given-names></name><name><surname>McKay</surname><given-names>RR</given-names></name><name><surname>Murphy</surname><given-names>JD</given-names></name><name><surname>Rose</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Low-value prostate-specific antigen screening in older males</article-title><source>JAMA Network Open</source><volume>6</volume><elocation-id>e237504</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.7504</pub-id><pub-id pub-id-type="pmid">37040113</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamada</surname><given-names>M</given-names></name><name><surname>So</surname><given-names>A</given-names></name><name><surname>Muramaki</surname><given-names>M</given-names></name><name><surname>Rocchi</surname><given-names>P</given-names></name><name><surname>Beraldi</surname><given-names>E</given-names></name><name><surname>Gleave</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells</article-title><source>Molecular Cancer Therapeutics</source><volume>6</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0417</pub-id><pub-id pub-id-type="pmid">17218637</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>TK</given-names></name><name><surname>Cherif</surname><given-names>C</given-names></name><name><surname>Omabe</surname><given-names>K</given-names></name><name><surname>Paris</surname><given-names>C</given-names></name><name><surname>Lannes</surname><given-names>F</given-names></name><name><surname>Audebert</surname><given-names>S</given-names></name><name><surname>Baudelet</surname><given-names>E</given-names></name><name><surname>Hamimed</surname><given-names>M</given-names></name><name><surname>Barbolosi</surname><given-names>D</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Bastide</surname><given-names>C</given-names></name><name><surname>Fazli</surname><given-names>L</given-names></name><name><surname>Gleave</surname><given-names>M</given-names></name><name><surname>Bertucci</surname><given-names>F</given-names></name><name><surname>Taïeb</surname><given-names>D</given-names></name><name><surname>Rocchi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer</article-title><source>Molecular Therapy</source><volume>31</volume><fpage>471</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2022.08.005</pub-id><pub-id pub-id-type="pmid">35965411</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hypertension and risk of prostate cancer: a systematic review and meta-analysis</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>31358</elocation-id><pub-id pub-id-type="doi">10.1038/srep31358</pub-id><pub-id pub-id-type="pmid">27511796</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lifshitz</surname><given-names>K</given-names></name><name><surname>Ber</surname><given-names>Y</given-names></name><name><surname>Margel</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of metabolic syndrome in prostate cancer development</article-title><source>European Urology Focus</source><volume>7</volume><fpage>508</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.euf.2021.04.022</pub-id><pub-id pub-id-type="pmid">33994167</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilja</surname><given-names>H</given-names></name><name><surname>Abrahamsson</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Three predominant proteins secreted by the human prostate gland</article-title><source>The Prostate</source><volume>12</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/pros.2990120105</pub-id><pub-id pub-id-type="pmid">3347596</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilja</surname><given-names>H</given-names></name><name><surname>Ulmert</surname><given-names>D</given-names></name><name><surname>Vickers</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prostate-specific antigen and prostate cancer: prediction, detection and monitoring</article-title><source>Nature Reviews. Cancer</source><volume>8</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nrc2351</pub-id><pub-id pub-id-type="pmid">18337732</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Lv</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>FJ</given-names></name><name><surname>Pan</surname><given-names>XW</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Cui</surname><given-names>XG</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>98117</fpage><lpage>98134</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20981</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luebke</surname><given-names>AM</given-names></name><name><surname>Attarchi-Tehrani</surname><given-names>A</given-names></name><name><surname>Meiners</surname><given-names>J</given-names></name><name><surname>Hube-Magg</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>DS</given-names></name><name><surname>Kluth</surname><given-names>M</given-names></name><name><surname>Höflmayer</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of</article-title><source>Cancer Biology &amp; Medicine</source><volume>16</volume><fpage>319</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2018.0384</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machiela</surname><given-names>MJ</given-names></name><name><surname>Lindström</surname><given-names>S</given-names></name><name><surname>Allen</surname><given-names>NE</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Barricarte</surname><given-names>A</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>HB</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Gapstur</surname><given-names>SM</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Krogh</surname><given-names>V</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Stevens</surname><given-names>VL</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Tjønneland</surname><given-names>A</given-names></name><name><surname>Travis</surname><given-names>R</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium</article-title><source>American Journal of Epidemiology</source><volume>176</volume><fpage>1121</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1093/aje/kws191</pub-id><pub-id pub-id-type="pmid">23193118</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Balkwill</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cancer-related inflammation</article-title><source>Nature</source><volume>454</volume><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1038/nature07205</pub-id><pub-id pub-id-type="pmid">18650914</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martuszewska</surname><given-names>D</given-names></name><name><surname>Ljungberg</surname><given-names>B</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Landberg</surname><given-names>G</given-names></name><name><surname>Oslakovic</surname><given-names>C</given-names></name><name><surname>Dahlbäck</surname><given-names>B</given-names></name><name><surname>Hafizi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e4350</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004350</pub-id><pub-id pub-id-type="pmid">19194507</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moradi</surname><given-names>A</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Batra</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment</article-title><source>Cancer Metastasis Reviews</source><volume>38</volume><fpage>333</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1007/s10555-019-09815-3</pub-id><pub-id pub-id-type="pmid">31659564</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>RK</given-names></name><name><surname>Reeves</surname><given-names>JR</given-names></name><name><surname>Toi</surname><given-names>A</given-names></name><name><surname>Dulude</surname><given-names>H</given-names></name><name><surname>Trachtenberg</surname><given-names>J</given-names></name><name><surname>Emami</surname><given-names>M</given-names></name><name><surname>Daigneault</surname><given-names>L</given-names></name><name><surname>Panchal</surname><given-names>C</given-names></name><name><surname>Sugar</surname><given-names>L</given-names></name><name><surname>Jewett</surname><given-names>MAS</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis</article-title><source>The Journal of Urology</source><volume>175</volume><fpage>1291</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)00695-6</pub-id><pub-id pub-id-type="pmid">16515983</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayerpour Dizaj</surname><given-names>T</given-names></name><name><surname>Doustmihan</surname><given-names>A</given-names></name><name><surname>Sadeghzadeh Oskouei</surname><given-names>B</given-names></name><name><surname>Akbari</surname><given-names>M</given-names></name><name><surname>Jaymand</surname><given-names>M</given-names></name><name><surname>Mazloomi</surname><given-names>M</given-names></name><name><surname>Jahanban-Esfahlan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Significance of PSCA as a novel prognostic marker and therapeutic target for cancer</article-title><source>Cancer Cell International</source><volume>24</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.1186/s12935-024-03320-6</pub-id><pub-id pub-id-type="pmid">38627732</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>EV</given-names></name><name><surname>Centenera</surname><given-names>MM</given-names></name><name><surname>Moldovan</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Irani</surname><given-names>S</given-names></name><name><surname>Vincent</surname><given-names>AD</given-names></name><name><surname>Chan</surname><given-names>H</given-names></name><name><surname>Horvath</surname><given-names>LG</given-names></name><name><surname>Lynn</surname><given-names>DJ</given-names></name><name><surname>Daly</surname><given-names>RJ</given-names></name><name><surname>Butler</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>17</volume><fpage>1470</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA118.000633</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa</surname><given-names>D</given-names></name><name><surname>Hercules</surname><given-names>A</given-names></name><name><surname>Carmona</surname><given-names>M</given-names></name><name><surname>Suveges</surname><given-names>D</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Malangone</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>I</given-names></name><name><surname>Miranda</surname><given-names>A</given-names></name><name><surname>Cruz-Castillo</surname><given-names>C</given-names></name><name><surname>Fumis</surname><given-names>L</given-names></name><name><surname>Bernal-Llinares</surname><given-names>M</given-names></name><name><surname>Tsukanov</surname><given-names>K</given-names></name><name><surname>Cornu</surname><given-names>H</given-names></name><name><surname>Tsirigos</surname><given-names>K</given-names></name><name><surname>Razuvayevskaya</surname><given-names>O</given-names></name><name><surname>Buniello</surname><given-names>A</given-names></name><name><surname>Schwartzentruber</surname><given-names>J</given-names></name><name><surname>Karim</surname><given-names>M</given-names></name><name><surname>Ariano</surname><given-names>B</given-names></name><name><surname>Martinez Osorio</surname><given-names>RE</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Machlitt-Northen</surname><given-names>S</given-names></name><name><surname>Gonzalez-Uriarte</surname><given-names>A</given-names></name><name><surname>Saha</surname><given-names>S</given-names></name><name><surname>Tirunagari</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>C</given-names></name><name><surname>Roldán-Romero</surname><given-names>JM</given-names></name><name><surname>Horswell</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>S</given-names></name><name><surname>Ghoussaini</surname><given-names>M</given-names></name><name><surname>Hulcoop</surname><given-names>DG</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>McDonagh</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The next-generation Open Targets Platform: reimagined, redesigned, rebuilt</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>D1353</fpage><lpage>D1359</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac1046</pub-id><pub-id pub-id-type="pmid">36399499</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ossoli</surname><given-names>A</given-names></name><name><surname>Wolska</surname><given-names>A</given-names></name><name><surname>Remaley</surname><given-names>AT</given-names></name><name><surname>Gomaraschi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>High-density lipoproteins: A promising tool against cancer</article-title><source>Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids</source><volume>1867</volume><elocation-id>159068</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbalip.2021.159068</pub-id><pub-id pub-id-type="pmid">34653581</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Péré-Brissaud</surname><given-names>A</given-names></name><name><surname>Blanchet</surname><given-names>X</given-names></name><name><surname>Delourme</surname><given-names>D</given-names></name><name><surname>Pélissier</surname><given-names>P</given-names></name><name><surname>Forestier</surname><given-names>L</given-names></name><name><surname>Delavaud</surname><given-names>A</given-names></name><name><surname>Duprat</surname><given-names>N</given-names></name><name><surname>Picard</surname><given-names>B</given-names></name><name><surname>Maftah</surname><given-names>A</given-names></name><name><surname>Brémaud</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Expression of SERPINA3s in cattle: focus on bovSERPINA3-7 reveals specific involvement in skeletal muscle</article-title><source>Open Biology</source><volume>5</volume><elocation-id>150071</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.150071</pub-id><pub-id pub-id-type="pmid">26562931</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Cornago</surname><given-names>A</given-names></name><name><surname>Dunneram</surname><given-names>Y</given-names></name><name><surname>Watts</surname><given-names>EL</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Travis</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Adiposity and risk of prostate cancer death: a prospective analysis in UK Biobank and meta-analysis of published studies</article-title><source>BMC Medicine</source><volume>20</volume><elocation-id>143</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-022-02336-x</pub-id><pub-id pub-id-type="pmid">35509091</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietzner</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>E</given-names></name><name><surname>Carrasco-Zanini</surname><given-names>J</given-names></name><name><surname>Cortes</surname><given-names>A</given-names></name><name><surname>Koprulu</surname><given-names>M</given-names></name><name><surname>Wörheide</surname><given-names>MA</given-names></name><name><surname>Oerton</surname><given-names>E</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>ID</given-names></name><name><surname>Kerrison</surname><given-names>ND</given-names></name><name><surname>Luan</surname><given-names>J</given-names></name><name><surname>Raffler</surname><given-names>J</given-names></name><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Arlt</surname><given-names>W</given-names></name><name><surname>O’Rahilly</surname><given-names>S</given-names></name><name><surname>Kastenmüller</surname><given-names>G</given-names></name><name><surname>Gamazon</surname><given-names>ER</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Scott</surname><given-names>RA</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mapping the proteo-genomic convergence of human diseases</article-title><source>Science</source><volume>374</volume><elocation-id>eabj1541</elocation-id><pub-id pub-id-type="doi">10.1126/science.abj1541</pub-id><pub-id pub-id-type="pmid">34648354</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohatgi</surname><given-names>A</given-names></name><name><surname>Westerterp</surname><given-names>M</given-names></name><name><surname>von Eckardstein</surname><given-names>A</given-names></name><name><surname>Remaley</surname><given-names>A</given-names></name><name><surname>Rye</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HDL in the 21st century: a multifunctional roadmap for future HDL research</article-title><source>Circulation</source><volume>143</volume><fpage>2293</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.044221</pub-id><pub-id pub-id-type="pmid">34097448</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosario</surname><given-names>SR</given-names></name><name><surname>Jacobi</surname><given-names>JJ</given-names></name><name><surname>Long</surname><given-names>MD</given-names></name><name><surname>Affronti</surname><given-names>HC</given-names></name><name><surname>Rowsam</surname><given-names>AM</given-names></name><name><surname>Smiraglia</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>JAZF1: a metabolic regulator of sensitivity to a polyamine-targeted therapy</article-title><source>Molecular Cancer Research</source><volume>21</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-22-0316</pub-id><pub-id pub-id-type="pmid">36166196</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruscica</surname><given-names>M</given-names></name><name><surname>Botta</surname><given-names>M</given-names></name><name><surname>Ferri</surname><given-names>N</given-names></name><name><surname>Giorgio</surname><given-names>E</given-names></name><name><surname>Macchi</surname><given-names>C</given-names></name><name><surname>Franceschini</surname><given-names>G</given-names></name><name><surname>Magni</surname><given-names>P</given-names></name><name><surname>Calabresi</surname><given-names>L</given-names></name><name><surname>Gomaraschi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High density lipoproteins inhibit oxidative stress-induced prostate cancer cell proliferation</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>2236</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-19568-8</pub-id><pub-id pub-id-type="pmid">29396407</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Maldonado</surname><given-names>JM</given-names></name><name><surname>Collado</surname><given-names>R</given-names></name><name><surname>Cabrera-Serrano</surname><given-names>AJ</given-names></name><name><surname>Ter Horst</surname><given-names>R</given-names></name><name><surname>Gálvez-Montosa</surname><given-names>F</given-names></name><name><surname>Robles-Fernández</surname><given-names>I</given-names></name><name><surname>Arenas-Rodríguez</surname><given-names>V</given-names></name><name><surname>Cano-Gutiérrez</surname><given-names>B</given-names></name><name><surname>Bakker</surname><given-names>O</given-names></name><name><surname>Bravo-Fernández</surname><given-names>MI</given-names></name><name><surname>García-Verdejo</surname><given-names>FJ</given-names></name><name><surname>López</surname><given-names>JAL</given-names></name><name><surname>Olivares-Ruiz</surname><given-names>J</given-names></name><name><surname>López-Nevot</surname><given-names>MÁ</given-names></name><name><surname>Fernández-Puerta</surname><given-names>L</given-names></name><name><surname>Cózar-Olmo</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Jurado</surname><given-names>M</given-names></name><name><surname>Lorente</surname><given-names>JA</given-names></name><name><surname>Sánchez-Rovira</surname><given-names>P</given-names></name><name><surname>Álvarez-Cubero</surname><given-names>MJ</given-names></name><name><surname>Sainz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Type 2 diabetes-related variants influence the risk of developing prostate cancer: a population-based case-control study and meta-analysis</article-title><source>Cancers</source><volume>14</volume><elocation-id>2376</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14102376</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>FR</given-names></name><name><surname>Olama</surname><given-names>AAA</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Benlloch</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Saunders</surname><given-names>EJ</given-names></name><name><surname>Dadaev</surname><given-names>T</given-names></name><name><surname>Leongamornlert</surname><given-names>D</given-names></name><name><surname>Anokian</surname><given-names>E</given-names></name><name><surname>Cieza-Borrella</surname><given-names>C</given-names></name><name><surname>Goh</surname><given-names>C</given-names></name><name><surname>Brook</surname><given-names>MN</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Fachal</surname><given-names>L</given-names></name><name><surname>Dennis</surname><given-names>J</given-names></name><name><surname>Tyrer</surname><given-names>J</given-names></name><name><surname>Muir</surname><given-names>K</given-names></name><name><surname>Lophatananon</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>VL</given-names></name><name><surname>Gapstur</surname><given-names>SM</given-names></name><name><surname>Carter</surname><given-names>BD</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Thompson</surname><given-names>IM</given-names><suffix>Jr</suffix></name><name><surname>Batra</surname><given-names>J</given-names></name><name><surname>Chambers</surname><given-names>S</given-names></name><name><surname>Moya</surname><given-names>L</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Horvath</surname><given-names>L</given-names></name><name><surname>Tilley</surname><given-names>W</given-names></name><name><surname>Risbridger</surname><given-names>GP</given-names></name><name><surname>Gronberg</surname><given-names>H</given-names></name><name><surname>Aly</surname><given-names>M</given-names></name><name><surname>Nordström</surname><given-names>T</given-names></name><name><surname>Pharoah</surname><given-names>P</given-names></name><name><surname>Pashayan</surname><given-names>N</given-names></name><name><surname>Schleutker</surname><given-names>J</given-names></name><name><surname>Tammela</surname><given-names>TLJ</given-names></name><name><surname>Sipeky</surname><given-names>C</given-names></name><name><surname>Auvinen</surname><given-names>A</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Weinstein</surname><given-names>S</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><name><surname>Håkansson</surname><given-names>N</given-names></name><name><surname>West</surname><given-names>CML</given-names></name><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>Burnet</surname><given-names>N</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Cussenot</surname><given-names>O</given-names></name><name><surname>Cancel-Tassin</surname><given-names>G</given-names></name><name><surname>Koutros</surname><given-names>S</given-names></name><name><surname>Beane Freeman</surname><given-names>LE</given-names></name><name><surname>Sorensen</surname><given-names>KD</given-names></name><name><surname>Orntoft</surname><given-names>TF</given-names></name><name><surname>Borre</surname><given-names>M</given-names></name><name><surname>Maehle</surname><given-names>L</given-names></name><name><surname>Grindedal</surname><given-names>EM</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name><name><surname>Donovan</surname><given-names>JL</given-names></name><name><surname>Hamdy</surname><given-names>FC</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Travis</surname><given-names>RC</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Hamilton</surname><given-names>RJ</given-names></name><name><surname>Fleshner</surname><given-names>NE</given-names></name><name><surname>Finelli</surname><given-names>A</given-names></name><name><surname>Ingles</surname><given-names>SA</given-names></name><name><surname>Stern</surname><given-names>MC</given-names></name><name><surname>Rosenstein</surname><given-names>BS</given-names></name><name><surname>Kerns</surname><given-names>SL</given-names></name><name><surname>Ostrer</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>HW</given-names></name><name><surname>Feng</surname><given-names>N</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>MacInnis</surname><given-names>RJ</given-names></name><name><surname>FitzGerald</surname><given-names>LM</given-names></name><name><surname>Kibel</surname><given-names>AS</given-names></name><name><surname>Drake</surname><given-names>BF</given-names></name><name><surname>Vega</surname><given-names>A</given-names></name><name><surname>Gómez-Caamaño</surname><given-names>A</given-names></name><name><surname>Szulkin</surname><given-names>R</given-names></name><name><surname>Eklund</surname><given-names>M</given-names></name><name><surname>Kogevinas</surname><given-names>M</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Castaño-Vinyals</surname><given-names>G</given-names></name><name><surname>Penney</surname><given-names>KL</given-names></name><name><surname>Stampfer</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Sellers</surname><given-names>TA</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Stanford</surname><given-names>JL</given-names></name><name><surname>Cybulski</surname><given-names>C</given-names></name><name><surname>Wokolorczyk</surname><given-names>D</given-names></name><name><surname>Lubinski</surname><given-names>J</given-names></name><name><surname>Ostrander</surname><given-names>EA</given-names></name><name><surname>Geybels</surname><given-names>MS</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Nielsen</surname><given-names>SF</given-names></name><name><surname>Weischer</surname><given-names>M</given-names></name><name><surname>Bisbjerg</surname><given-names>R</given-names></name><name><surname>Røder</surname><given-names>MA</given-names></name><name><surname>Iversen</surname><given-names>P</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Cuk</surname><given-names>K</given-names></name><name><surname>Holleczek</surname><given-names>B</given-names></name><name><surname>Maier</surname><given-names>C</given-names></name><name><surname>Luedeke</surname><given-names>M</given-names></name><name><surname>Schnoeller</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Logothetis</surname><given-names>CJ</given-names></name><name><surname>John</surname><given-names>EM</given-names></name><name><surname>Teixeira</surname><given-names>MR</given-names></name><name><surname>Paulo</surname><given-names>P</given-names></name><name><surname>Cardoso</surname><given-names>M</given-names></name><name><surname>Neuhausen</surname><given-names>SL</given-names></name><name><surname>Steele</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>YC</given-names></name><name><surname>De Ruyck</surname><given-names>K</given-names></name><name><surname>De Meerleer</surname><given-names>G</given-names></name><name><surname>Ost</surname><given-names>P</given-names></name><name><surname>Razack</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Teo</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>DW</given-names></name><name><surname>Newcomb</surname><given-names>LF</given-names></name><name><surname>Lessel</surname><given-names>D</given-names></name><name><surname>Gamulin</surname><given-names>M</given-names></name><name><surname>Kulis</surname><given-names>T</given-names></name><name><surname>Kaneva</surname><given-names>R</given-names></name><name><surname>Usmani</surname><given-names>N</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Slavov</surname><given-names>C</given-names></name><name><surname>Mitev</surname><given-names>V</given-names></name><name><surname>Parliament</surname><given-names>M</given-names></name><name><surname>Claessens</surname><given-names>F</given-names></name><name><surname>Joniau</surname><given-names>S</given-names></name><name><surname>Van den Broeck</surname><given-names>T</given-names></name><name><surname>Larkin</surname><given-names>S</given-names></name><name><surname>Townsend</surname><given-names>PA</given-names></name><name><surname>Aukim-Hastie</surname><given-names>C</given-names></name><name><surname>Gago-Dominguez</surname><given-names>M</given-names></name><name><surname>Castelao</surname><given-names>JE</given-names></name><name><surname>Martinez</surname><given-names>ME</given-names></name><name><surname>Roobol</surname><given-names>MJ</given-names></name><name><surname>Jenster</surname><given-names>G</given-names></name><name><surname>van Schaik</surname><given-names>RHN</given-names></name><name><surname>Menegaux</surname><given-names>F</given-names></name><name><surname>Truong</surname><given-names>T</given-names></name><name><surname>Koudou</surname><given-names>YA</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Cannon-Albright</surname><given-names>L</given-names></name><name><surname>Pandha</surname><given-names>H</given-names></name><name><surname>Michael</surname><given-names>A</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Lindstrom</surname><given-names>S</given-names></name><name><surname>Turman</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Siddiq</surname><given-names>A</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Hoover</surname><given-names>RN</given-names></name><name><surname>Machiela</surname><given-names>MJ</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Conti</surname><given-names>DV</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Wiklund</surname><given-names>F</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><collab>Profile Study</collab><collab>Australian Prostate Cancer BioResource</collab><collab>IMPACT Study</collab><collab>Canary PASS Investigators</collab><collab>Breast and Prostate Cancer Cohort Consortium</collab><collab>PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium</collab><collab>Cancer of the Prostate in Sweden</collab><collab>Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS)</collab><collab>Genetic Associations and Mechanisms in Oncology/Elucidating Loci Involved in Prostate Cancer Susceptibility Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci</article-title><source>Nature Genetics</source><volume>51</volume><elocation-id>363</elocation-id><pub-id pub-id-type="doi">10.1038/s41588-018-0330-6</pub-id><pub-id pub-id-type="pmid">30622367</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seretis</surname><given-names>A</given-names></name><name><surname>Cividini</surname><given-names>S</given-names></name><name><surname>Markozannes</surname><given-names>G</given-names></name><name><surname>Tseretopoulou</surname><given-names>X</given-names></name><name><surname>Lopez</surname><given-names>DS</given-names></name><name><surname>Ntzani</surname><given-names>EE</given-names></name><name><surname>Tsilidis</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>8565</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-45014-4</pub-id><pub-id pub-id-type="pmid">31189941</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Bishop</surname><given-names>JL</given-names></name><name><surname>Nip</surname><given-names>KM</given-names></name><name><surname>Zardan</surname><given-names>A</given-names></name><name><surname>Takeuchi</surname><given-names>A</given-names></name><name><surname>Cordonnier</surname><given-names>T</given-names></name><name><surname>Beraldi</surname><given-names>E</given-names></name><name><surname>Bazov</surname><given-names>J</given-names></name><name><surname>Fazli</surname><given-names>L</given-names></name><name><surname>Chi</surname><given-names>K</given-names></name><name><surname>Gleave</surname><given-names>M</given-names></name><name><surname>Zoubeidi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer</article-title><source>Cancer Research</source><volume>73</volume><fpage>3109</fpage><lpage>3119</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3979</pub-id><pub-id pub-id-type="pmid">23492367</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjöblom</surname><given-names>L</given-names></name><name><surname>Saramäki</surname><given-names>O</given-names></name><name><surname>Annala</surname><given-names>M</given-names></name><name><surname>Leinonen</surname><given-names>K</given-names></name><name><surname>Nättinen</surname><given-names>J</given-names></name><name><surname>Tolonen</surname><given-names>T</given-names></name><name><surname>Wahlfors</surname><given-names>T</given-names></name><name><surname>Nykter</surname><given-names>M</given-names></name><name><surname>Bova</surname><given-names>GS</given-names></name><name><surname>Schleutker</surname><given-names>J</given-names></name><name><surname>Tammela</surname><given-names>TLJ</given-names></name><name><surname>Lilja</surname><given-names>H</given-names></name><name><surname>Visakorpi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Microseminoprotein-beta expression in different stages of prostate cancer</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0150241</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0150241</pub-id><pub-id pub-id-type="pmid">26939004</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith Byrne</surname><given-names>K</given-names></name><name><surname>Appleby</surname><given-names>PN</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Holmes</surname><given-names>MV</given-names></name><name><surname>Fensom</surname><given-names>GK</given-names></name><name><surname>Agudo</surname><given-names>A</given-names></name><name><surname>Ardanaz</surname><given-names>E</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>HB</given-names></name><name><surname>Chirlaque</surname><given-names>MD</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Larrañaga</surname><given-names>N</given-names></name><name><surname>Palli</surname><given-names>D</given-names></name><name><surname>Perez-Cornago</surname><given-names>A</given-names></name><name><surname>Quirós</surname><given-names>JR</given-names></name><name><surname>Ricceri</surname><given-names>F</given-names></name><name><surname>Sánchez</surname><given-names>MJ</given-names></name><name><surname>Tagliabue</surname><given-names>G</given-names></name><name><surname>Tsilidis</surname><given-names>KK</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Fortner</surname><given-names>RT</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Lilja</surname><given-names>H</given-names></name><name><surname>Travis</surname><given-names>RC</given-names></name><collab>PRACTICAL Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition</article-title><source>Annals of Oncology</source><volume>30</volume><fpage>983</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz121</pub-id><pub-id pub-id-type="pmid">31089709</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stikbakke</surname><given-names>E</given-names></name><name><surname>Schirmer</surname><given-names>H</given-names></name><name><surname>Knutsen</surname><given-names>T</given-names></name><name><surname>Støyten</surname><given-names>M</given-names></name><name><surname>Wilsgaard</surname><given-names>T</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name><name><surname>McTiernan</surname><given-names>A</given-names></name><name><surname>Eggen</surname><given-names>AE</given-names></name><name><surname>Haugnes</surname><given-names>HS</given-names></name><name><surname>Richardsen</surname><given-names>E</given-names></name><name><surname>Thune</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival: The PROCA-life study</article-title><source>Cancer Medicine</source><volume>11</volume><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1002/cam4.4523</pub-id><pub-id pub-id-type="pmid">34939344</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>BB</given-names></name><name><surname>Chiou</surname><given-names>J</given-names></name><name><surname>Traylor</surname><given-names>M</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>Y-H</given-names></name><name><surname>Richardson</surname><given-names>TG</given-names></name><name><surname>Surendran</surname><given-names>P</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Robins</surname><given-names>C</given-names></name><name><surname>Vasquez-Grinnell</surname><given-names>SG</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Kvikstad</surname><given-names>EM</given-names></name><name><surname>Burren</surname><given-names>OS</given-names></name><name><surname>Davitte</surname><given-names>J</given-names></name><name><surname>Ferber</surname><given-names>KL</given-names></name><name><surname>Gillies</surname><given-names>CE</given-names></name><name><surname>Hedman</surname><given-names>ÅK</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Mikkilineni</surname><given-names>R</given-names></name><name><surname>Pendergrass</surname><given-names>RK</given-names></name><name><surname>Pickering</surname><given-names>C</given-names></name><name><surname>Prins</surname><given-names>B</given-names></name><name><surname>Baird</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>C-Y</given-names></name><name><surname>Ward</surname><given-names>LD</given-names></name><name><surname>Deaton</surname><given-names>AM</given-names></name><name><surname>Welsh</surname><given-names>S</given-names></name><name><surname>Willis</surname><given-names>CM</given-names></name><name><surname>Lehner</surname><given-names>N</given-names></name><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Wörheide</surname><given-names>MA</given-names></name><name><surname>Suhre</surname><given-names>K</given-names></name><name><surname>Kastenmüller</surname><given-names>G</given-names></name><name><surname>Sethi</surname><given-names>A</given-names></name><name><surname>Cule</surname><given-names>M</given-names></name><name><surname>Raj</surname><given-names>A</given-names></name><name><surname>Burkitt-Gray</surname><given-names>L</given-names></name><name><surname>Melamud</surname><given-names>E</given-names></name><name><surname>Black</surname><given-names>MH</given-names></name><name><surname>Fauman</surname><given-names>EB</given-names></name><name><surname>Howson</surname><given-names>JMM</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Nioi</surname><given-names>P</given-names></name><name><surname>Petrovski</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>EN</given-names></name><name><surname>Szalma</surname><given-names>S</given-names></name><name><surname>Waterworth</surname><given-names>DM</given-names></name><name><surname>Mitnaul</surname><given-names>LJ</given-names></name><name><surname>Szustakowski</surname><given-names>JD</given-names></name><name><surname>Gibson</surname><given-names>BW</given-names></name><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Whelan</surname><given-names>CD</given-names></name><collab>Alnylam Human Genetics</collab><collab>AstraZeneca Genomics Initiative</collab><collab>Biogen Biobank Team</collab><collab>Bristol Myers Squibb</collab><collab>Genentech Human Genetics</collab><collab>GlaxoSmithKline Genomic Sciences</collab><collab>Pfizer Integrative Biology</collab><collab>Population Analytics of Janssen Data Sciences</collab><collab>Regeneron Genetics Center</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Plasma proteomic associations with genetics and health in the UK Biobank</article-title><source>Nature</source><volume>622</volume><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06592-6</pub-id><pub-id pub-id-type="pmid">37794186</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Jeong</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kwon</surname><given-names>W</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>M-H</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Ha</surname><given-names>Y-S</given-names></name><name><surname>Kwon</surname><given-names>TG</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Ryoo</surname><given-names>ZY</given-names></name><name><surname>Kim</surname><given-names>MO</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Jazf1 promotes prostate cancer progression by activating JNK/Slug</article-title><source>Oncotarget</source><volume>9</volume><fpage>755</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23146</pub-id><pub-id pub-id-type="pmid">29416651</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikkinen</surname><given-names>KAO</given-names></name><name><surname>Dahm</surname><given-names>P</given-names></name><name><surname>Lytvyn</surname><given-names>L</given-names></name><name><surname>Heen</surname><given-names>AF</given-names></name><name><surname>Vernooij</surname><given-names>RWM</given-names></name><name><surname>Siemieniuk</surname><given-names>RAC</given-names></name><name><surname>Wheeler</surname><given-names>R</given-names></name><name><surname>Vaughan</surname><given-names>B</given-names></name><name><surname>Fobuzi</surname><given-names>AC</given-names></name><name><surname>Blanker</surname><given-names>MH</given-names></name><name><surname>Junod</surname><given-names>N</given-names></name><name><surname>Sommer</surname><given-names>J</given-names></name><name><surname>Stirnemann</surname><given-names>J</given-names></name><name><surname>Yoshimura</surname><given-names>M</given-names></name><name><surname>Auer</surname><given-names>R</given-names></name><name><surname>MacDonald</surname><given-names>H</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Vandvik</surname><given-names>PO</given-names></name><name><surname>Agoritsas</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline</article-title><source>BMJ</source><volume>362</volume><elocation-id>k3581</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.k3581</pub-id><pub-id pub-id-type="pmid">30185545</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Bi</surname><given-names>HX</given-names></name><name><surname>Kai</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>RY</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells</article-title><source>Asian Journal of Andrology</source><volume>24</volume><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.4103/aja2021114</pub-id><pub-id pub-id-type="pmid">34975070</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urysiak-Czubatka</surname><given-names>I</given-names></name><name><surname>Kmieć</surname><given-names>ML</given-names></name><name><surname>Broniarczyk-Dyła</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia</article-title><source>Postepy Dermatologii I Alergologii</source><volume>31</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.5114/pdia.2014.40925</pub-id><pub-id pub-id-type="pmid">25254005</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasiljević</surname><given-names>N</given-names></name><name><surname>Ahmad</surname><given-names>AS</given-names></name><name><surname>Beesley</surname><given-names>C</given-names></name><name><surname>Thorat</surname><given-names>MA</given-names></name><name><surname>Fisher</surname><given-names>G</given-names></name><name><surname>Berney</surname><given-names>DM</given-names></name><name><surname>Møller</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>YJ</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name><name><surname>Lorincz</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer</article-title><source>Prostate Cancer and Prostatic Diseases</source><volume>16</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/pcan.2012.47</pub-id><pub-id pub-id-type="pmid">23165430</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Balmat</surname><given-names>TJ</given-names></name><name><surname>Antonia</surname><given-names>AL</given-names></name><name><surname>Constantine</surname><given-names>FJ</given-names></name><name><surname>Henao</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>TW</given-names></name><name><surname>Ingham</surname><given-names>A</given-names></name><name><surname>McClain</surname><given-names>MT</given-names></name><name><surname>Tsalik</surname><given-names>EL</given-names></name><name><surname>Ko</surname><given-names>ER</given-names></name><name><surname>Ginsburg</surname><given-names>GS</given-names></name><name><surname>DeLong</surname><given-names>MR</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Woods</surname><given-names>CW</given-names></name><name><surname>Hauser</surname><given-names>ER</given-names></name><name><surname>Ko</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.20.20248572</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Taskesen</surname><given-names>E</given-names></name><name><surname>van Bochoven</surname><given-names>A</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Functional mapping and annotation of genetic associations with FUMA</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1826</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01261-5</pub-id><pub-id pub-id-type="pmid">29184056</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitaker</surname><given-names>HC</given-names></name><name><surname>Warren</surname><given-names>AY</given-names></name><name><surname>Eeles</surname><given-names>R</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target</article-title><source>The Prostate</source><volume>70</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1002/pros.21059</pub-id><pub-id pub-id-type="pmid">19790236</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Shao</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Long Non-coding RNA AGAP2-AS1 silencing inhibits PDLIM5 expression impeding prostate cancer progression <italic>via</italic> up-regulation of microRNA-195-5p</article-title><source>Frontiers in Genetics</source><volume>11</volume><elocation-id>1030</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2020.01030</pub-id><pub-id pub-id-type="pmid">33101368</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>CJ</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>WW</given-names></name><name><surname>Sun</surname><given-names>MM</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Zhao</surname><given-names>ZH</given-names></name><name><surname>Jiang</surname><given-names>GZ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression</article-title><source>Artificial Cells, Nanomedicine, and Biotechnology</source><volume>47</volume><fpage>3920</fpage><lpage>3928</lpage><pub-id pub-id-type="doi">10.1080/21691401.2019.1671856</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Sa</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>EEFSEC knockdown inhibits proliferation, migration and invasion of prostate cancer cells <italic>in vitro</italic></article-title><source>Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University</source><volume>41</volume><fpage>1787</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.12122/j.issn.1673-4254.2021.12.05</pub-id><pub-id pub-id-type="pmid">35012909</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>GY</given-names></name><name><surname>Su</surname><given-names>WC</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Tang</surname><given-names>QY</given-names></name><name><surname>Liu</surname><given-names>YX</given-names></name><name><surname>Wang</surname><given-names>SZ</given-names></name><name><surname>Li</surname><given-names>WC</given-names></name><name><surname>Wesselius</surname><given-names>A</given-names></name><name><surname>Zeegers</surname><given-names>MP</given-names></name><name><surname>Zhang</surname><given-names>ZY</given-names></name><name><surname>Gu</surname><given-names>YH</given-names></name><name><surname>Tao</surname><given-names>WA</given-names></name><name><surname>Yu</surname><given-names>EYW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>High throughput isolation and data independent acquisition mass spectrometry (DIA-MS) of urinary extracellular vesicles to improve prostate cancer diagnosis</article-title><source>Molecules</source><volume>27</volume><elocation-id>8155</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27238155</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>CW</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MLL3 suppresses tumorigenesis through regulating TNS3 enhancer activity</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-03647-2</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>MY</given-names></name><name><surname>Li</surname><given-names>KK</given-names></name><name><surname>Luo</surname><given-names>KQ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Shear stress drives the cleavage activation of protease‐activated receptor 2 by PRSS3/Mesotrypsin to promote invasion and metastasis of circulating lung cancer cells</article-title><source>Advanced Science</source><volume>10</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202301059</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuidema</surname><given-names>A</given-names></name><name><surname>Atherton</surname><given-names>P</given-names></name><name><surname>Kreft</surname><given-names>M</given-names></name><name><surname>Hoekman</surname><given-names>L</given-names></name><name><surname>Bleijerveld</surname><given-names>OB</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Fässler</surname><given-names>R</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PEAK1 Y635 phosphorylation regulates cell migration through association with Tensin3 and integrins</article-title><source>The Journal of Cell Biology</source><volume>221</volume><elocation-id>e202108027</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.202108027</pub-id><pub-id pub-id-type="pmid">35687021</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101584.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cullen</surname><given-names>Jennifer</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Case Western Reserve University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Incomplete</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>This study presents a meta-analysis of two independent genome-wide association studies (GWAS) that investigate the role of plasma proteins as potential biomarkers for enhancing the early detection of prostate cancer (PCa). The results provide <bold>useful</bold> confirmatory data that support existing evidence currently published. The evidence is <bold>incomplete</bold>: the study does not provide a comprehensive synthesis of all currently published work, does not explore other clinical outcomes related to prostatic disease, and its findings have not been validated through an external cohort study. These shortcomings notwithstanding, the work may be of interest to researchers studying correlates and predictors of prostate cancer risk.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101584.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization the authors present a manuscript which seeks to identify novel markers for prostate cancer through analysis of large biobank-based datasets, and to extend this analysis to potential therapeutic targets for drugs. This is an area which is already extensively researched, but remains important, due to the high burden and mortality of prostate cancer globally.</p><p>Strengths:</p><p>The main strengths of the manuscript are the identification and use of large biobank data assets, which provide large numbers of cases and controls, essential for achieving statistical power. The databases used (deCODE, FinnGen and the UK Biobank) allow for robust numbers of cases and controls. The analytical method chosen, Mendelian Randomization, however, may not be appropriate to the problem (without extensive validation, MR can be prone to false or misleading discoveries). The manuscript also integrates multi-omic datasets, here using protein data as well as GWAS sources to integrate genomic and proteomic data.</p><p>Weaknesses:</p><p>The main weaknesses of the manuscript relate to the following areas:</p><p>(1) The failure of the study to analyse the data in the context of other closely related conditions such as benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS), which have some pathways and biomarkers in common, such as inflammatory pathways (including complement) and specific markers such as KLK3. As a consequence, it is not possible for readers to know whether the findings are specific to prostate cancer, or whether they are generic to prostate dysfunction. Given the prevalence of prostate dysfunction (half of men reaching their sixth decade), the potential for false positives and overtreatment from non-specific biomarkers is a major problem, resulting in the evidence presented in this manuscript being weak. Other researchers have addressed this issue using the same data sources as presented here, for example in this paper looking at BPH in the UK Biobank population.</p><p><ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41467-018-06920-9">https://www.nature.com/articles/s41467-018-06920-9</ext-link></p><p>(2) There is no discussion of Gleason scores with regard to either biomarkers or therapies, and a general lack of discussion around indolent disease as compared with more aggressive variants. These are crucial issues with regard to the triage and identification of genomically aggressive localized prostate cancers. See for example the work set out in: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature20788">https://doi.org/10.1038/nature20788</ext-link>. In the revised version of the manuscript the authors set this out as a limitation, but this does not solve the core problem, which is that without this important biological context, the findings are unlikely to be robust.</p><p>(3) An additional issue is that the field of PCa research is fast-moving. The manuscript cites ~80 references, but too few of these are from recent studies and many important and relevant papers are not included. The manuscript would be much stronger if it compared and contrasted its findings with more recent studies of PCa biomarkers and targets, especially those concerned with multi-omics and those including BPH. In the latest revised version of the manuscript, some changes have been made, but the source data are still too limited for in-depth analysis.</p><p>(4) The Methods section provides no information on how the Controls were selected. There is no Table providing cohort data to allow the reader to know whether there were differences in age, BMI, ethnic grouping, social status or deprivation, or smoking status, between the Cases and Controls. These types of data are generally recorded in Biobank data; in the latest version of the manuscript the authors state that they don't have any ability to derive matched data, which again prevents deep analysis of the data.</p><p>Assessing impact:</p><p>Because of the weaknesses of the approach identified above, without further additions to the manuscript, the likely impact of the work on the field is minimal. There is no significant utility of the methods and data to the community, because the data are pre-existing and are not newly introduced to the community in this work, and mendelian randomization is a well-described approach in common use, and therefore the assets and methods described in the manuscript are not novel. In addition, Mendelian randomization is not always appropriate, especially when analysing publicly available data, see:</p><p>Stender et al. Lipids in Health and Disease (2024) 23:286</p><p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12944-024-02284-w">https://doi.org/10.1186/s12944-024-02284-w</ext-link></p><p>With regard to the authors achieving their aims, without assessing specificity and without setting their findings in the context of the latest literature, the authors (and readers) cannot know or assess whether the biomarkers identified or the druggable targets will be useful in the clinic.</p><p>In conclusion, adding additional context and analysis to the manuscript would both help readers interpret and understand the work, and would also greatly enhance its significance. For example, the UK Biobank includes data on men with BPH / LUTS, as analysed in this paper, for example, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-018-06920-9">https://doi.org/10.1038/s41467-018-06920-9</ext-link>. In the latest version of the manuscript and through the responses to earlier review comments, the authors explain why this has not been possible, but this naturally limits the value of the research.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101584.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This is potentially interesting work, but the analyses are attempted in a rather scattergun way, with little evident critical thought. The structure of the work (Results before Methods) can work in some manuscripts, but it is not ideal here. The authors discuss results before we know anything about the underlying data that the results come from. It gives the impression that the authors regard data as a resource to be exploited, without really caring where the data comes from. The methods can provide meaningful insights if correctly used, but while I don't have reasons to doubt that the analyses were conducted correctly, findings are presented with little discussion or interpretation. No follow-up analyses are performed.</p><p>This is much improved but there remain some small concerns and one large concern:</p><p>Using numbering from the previous review:</p><p>(1) This looks better, but I still don't understand the claim in the text: &quot;We found 5 genetic risk loci contained at least one SNP passing the genome-wide significance threshold of P {less than or equal to} 5×10−8&quot;. Far more gene regions appear to cross 10^-8 in Figure 1. What am I missing?</p><p>(6) I don't understand the authors' response here. Early detection is important, but MR is not the right tool to investigate biomarkers for early detection. Biomarkers for early detection do not have to be causal biomarkers. The authors replied to this point, but the manuscript was unchanged.</p><p>(7) Again, the authors still state &quot;193 proteins were associated with PCa risk&quot; even though they acknowledge that their analysis does not test whether proteins associate with PCa risk or not. When an error is pointed out, and you acknowledge it, please change the manuscript to correct the text. Otherwise, what is the peer review process for?</p><p>The large concern is that these analyses, while now better explained, are still the product of a semi-automated procedure. It is a good procedure, but the manuscript essentially takes public data from different sources and uses this to create a manuscript. Overall, I think there is enough novel synthesis to justify publication, but it is not automatic.</p><p>Strengths:</p><p>The data and methods used are state-of-the-art.</p><p>Weaknesses:</p><p>The reader will have to provide their own translational insight.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101584.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary of concerns about the revised submission from the Reviewing Editor:</p><p>With respect to Originality of the work, in the last 18 months, there have been 38 publications on combined topics of: (i) UK Biobank data, (ii) Mendelian randomization, (iii) and prostate cancer. The authors should consider the literature addressing prostate cancer via Mendelian randomization--specifically those using the UK Biobank data--published from 2024 onwards. A proper and comprehensive synthesis of recent findings should be made, to allow readers to compare and contrast how the work supports (or differs) from the findings presented in these other published studies.</p><p>With respect to the significance of the findings, we feel the study data are incomplete for the strength of evidence. Given the deluge of manuscripts and publications on similar topics, the study offers incremental evidence and lacks a synthesis of all currently published findings.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101584.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Lin</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University First Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Yanlun</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University First Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yuke</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Urology Surgery, Peking University First Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Wei</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Urology Surgery, Peking University First Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Ying</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University First Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Rong</surname><given-names>Zhuona</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University First Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Pang</surname><given-names>Xiaocong</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University First Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>In Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization, the authors present a manuscript which seeks to identify novel markers for prostate cancer through analysis of large biobank-based datasets and to extend this analysis to potential therapeutic targets for drugs. This is an area that is already extensively researched, but remains important, due to the high burden and mortality of prostate cancer globally.</p><p>Strengths:</p><p>The main strengths of the manuscript are the identification and use of large biobank data assets, which provide large numbers of cases and controls, essential for achieving statistical power. The databases used (deCODE, FinnGen, and the UK Biobank) allow for robust numbers of cases and controls. The analytical method chosen, Mendelian Randomization, is appropriate to the problem. Another strength is the integration of multi-omic datasets, here using protein data as well as GWAS sources to integrate genomic and proteomic data.</p></disp-quote><p>Thank you for your positive feedback regarding the overall quality of our work and we greatly appreciate you taking time and making effort in reviewing our manuscript.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The main weaknesses of the manuscript relate to the following areas:</p><p>(1) The failure of the study to analyse the data in the context of other closely related conditions such as benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS), which have some pathways and biomarkers in common, such as inflammatory pathways (including complement) and specific markers such as KLK3. As a consequence, it is not possible for readers to know whether the findings are specific to prostate cancer or whether they are generic to prostate dysfunction. Given the prevalence of prostate dysfunction (half of men reaching their sixth decade), the potential for false positives and overtreatment from non-specific biomarkers is a major problem, resulting in the evidence presented in this manuscript being weak. Other researchers have addressed this issue using the same data sources as presented here, for example, in this paper, looking at BPH in the UK Biobank population. <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41467-018-06920-9">https://www.nature.com/articles/s41467-018-06920-9</ext-link></p></disp-quote><p>Thank you for your valuable comment. We fully agree that biomarker development must prioritize specificity to avoid overtreatment. While our study is a foundational step toward identifying potential therapeutic targets or complementary biomarkers for prostate cancer—not as a direct endorsement of these proteins for standalone clinical diagnosis. Mendelian randomization analysis strengthens causal inference by design, and we further ensured robustness through sensitivity analyses (e.g., MR-Egger regression for pleiotropy, Bonferroni correction for multiple testing). These methods distinguish true causal effects from nonspecific associations. Importantly, while PSA’s lack of specificity is widely recognized, its role in reducing PCa mortality underscores the value of biomarker-driven screening. Our findings align with the need to integrate multiple markers (e.g. combining a novel protein with PSA) to improve diagnostic precision. Translating these causal insights into clinical tools remains challenging but represents a necessary next step, and we emphasize that this work provides a rigorous starting point for future validation studies.</p><disp-quote content-type="editor-comment"><p>(2) There is no discussion of Gleason scores with regard to either biomarkers or therapies, and a general lack of discussion around indolent disease as compared with more aggressive variants. These are crucial issues with regard to the triage and identification of genomically aggressive localized prostate cancers. See, for example, the work set out in: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature20788">https://doi.org/10.1038/nature20788</ext-link></p></disp-quote><p>Thank you for pointing this out. We acknowledge that our original analysis did not directly address this critical issue due to a key data limitation: the publicly available GWAS summary statistics for PCa (from openGWAS and FinnGen) do not provide genetic associations stratified by phenotypic severity or molecular subtypes. This limitation precluded MR analysis of proteins specifically linked to aggressive disease. To partially bridge this gap, we integrate evidence from recent studies in the revised Discussion section to explore the relevance of potential biomarkers to aggressive PCa.</p><disp-quote content-type="editor-comment"><p>(3) An additional issue is that the field of PCa research is fast-moving. The manuscript cites ~80 references, but too few of these are from recent studies, and many important and relevant papers are not included. The manuscript would be much stronger if it compared and contrasted its findings with more recent studies of PCa biomarkers and targets, especially those concerned with multi-omics and those including BPH.</p></disp-quote><p>Thank you for your professional comments. We have rigorously updated the manuscript to include more recent publications and we systematically compare and contrast our findings with these recent studies in the revised Discussion section.</p><disp-quote content-type="editor-comment"><p>(4) The Methods section provides no information on how the Controls were selected. There is no Table providing cohort data to allow the reader to know whether there were differences in age, BMI, ethnic grouping, social status or deprivation, or smoking status, between the Cases and Controls. These types of data are generally recorded in Biobank data, so this sort of analysis should be possible, or if not, the authors' inability to construct an appropriately matched set of Controls should be discussed as a Limitation.</p></disp-quote><p>We thank the reviewer for raising this important methodological concern. We have expanded the Limitations section to state it.</p><p>“Lastly, our analysis relied exclusively on publicly available GWAS summary statistics from openGWAS and FinnGen, which did not provide individual-level data on covariates, resulting in no direct assessment of demographic or clinical differences between cases and controls.”</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>This is potentially interesting work, but the analyses are attempted in a rather scattergun way, with little evident critical thought. The structure of the work (Results before Methods) can work in some manuscripts, but it is not ideal here. The authors discuss results before we know anything about the underlying data that the results come from. It gives the impression that the authors regard data as a resource to be exploited, without really caring where the data comes from. The methods can provide meaningful insights if correctly used, but while I don't have reasons to doubt that the analyses were conducted correctly, findings are presented with little discussion or interpretation. No follow-up analyses are performed.</p><p>In summary, there are likely some gems here, but the whole manuscript is essentially the output from an analytic pipeline.</p></disp-quote><p>We thank the reviewer for the thoughtful evaluation of our work. In response to the concerns regarding manuscript structure and interpretative depth, we have restructured the manuscript to present the Methods section before Results, ensuring transparency in data sources and analytical workflows. Additionally, the Discussion section has been substantially revised to provide mechanistic explanations for key findings (e.g., associated phenotype, causal proteins, druggable targets), contextualize results within recent multi-omics studies and highlight clinical implications. These revisions aim to transform the work from a pipeline-driven analysis to a biologically grounded investigation, offering actionable insights into prostate cancer pathogenesis and therapeutic development.</p><disp-quote content-type="editor-comment"><p>Taking the researchers aims in turn:</p><p>(1) Meta-GWAS - while combining two datasets together can provide additional insights, the contribution of this analysis above existing GWAS is not clear. The PRACTICAL consortium has already reported the GWAS of 70% of these data. What additional value does this analysis provide? (Likely some, but it's not clear from the text.) Also, the presentation of results is unclear - authors state that only 5 gene regions contained variants at p&lt;5x10-8, but Figure 1 shows dozens of hits above 5x10-8. Also, the red line in Figure 1 (supposedly at 5x10-8) is misplaced.</p></disp-quote><p>Thank you very much for your feedback. Although the PRACTICAL consortium constituted the majority of PCa GWAS data, our meta-analysis integrating FinnGen data enhanced statistical power enabling robust detection of low-frequency variants with minor allele frequencies. Moreover, FinnGen's Finnish ancestry (genetic isolate) helps distinguish population-specific effects. The presentation of results showed the top 5 gene regions contained variants at p &lt; 5×10⁻⁸. We apologize for not noticing that the red line was not displayed correctly in the original figures included in the manuscript. We have updated it in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(2) Cross-phenotype analysis. It is not really clear what this analysis is, or why it is done. What is the iCPAGdb? A database? A statistical method? Why would we want to know cross-phenotype associations? What even are these? It seems that the authors have taken data from an online resource and have written a paragraph based on this existing data with little added value.</p></disp-quote><p>We appreciate the opportunity to clarify this analysis. The cross-phenotype analysis was designed to systematically identify phenotypic traits that share genetic or molecular pathways with prostate cancer, thereby uncovering pleiotropic mechanisms or shared risk factors. Here, iCPAGdb (integrated Cross-Phenotype Association Genetics Database) is a curated repository that aggregates GWAS summary statistics and evaluates genetic pleiotropy using LD-proxy associations from the NHGRI-EBI GWAS Catalog. Prostate carcinogenesis involves multisystem interactions, including spanning endocrine dysregulation, immune microenvironment remodeling and metabolic reprogramming, rather than isolated molecular pathway disruptions. Therefore, it is indispensable for discriminating primary pathogenic drivers from secondary compensatory responses, ultimately informing the development of precision therapeutic strategies.</p><p>In response to your concerns, we have revised the Results section to explicitly define the rationale and methodology of cross-phenotype analysis and restructured the Discussion to interpret phenotype-PCa associations within unified biological frameworks (e.g., metabolic dysregulation, androgen signaling), rather than presenting them as isolated findings.</p><disp-quote content-type="editor-comment"><p>(3) PW-MR. I can see the value of this work, but many details are unclear. Was this a two-sample MR using PRACTICAL + FinnGen data for the outcome? How many variants were used in key analyses? Again, the description of results is sparse and gives little added value.</p></disp-quote><p>We thank you for raising this issue. Two-sample MR refers to an analytical design where genetic instruments for the exposure (plasma proteins) and genetic associations with the outcome (PCa) are derived from non-overlapping populations. This ensures complete sample independence between exposure and outcome datasets to avoid confounding biases, regardless of whether the outcome data originate from single or multiple cohorts. The meta-analysis of PRACTICAL and FinnGen GWAS generates 27,210 quality-controlled variants (p &lt; 5×10⁻⁸, MAF ≥ 1%, LD-clumped r² &lt; 0.1) used in key analyses. Regarding the concern about sparse interpretation, we have substantially expanded the Discussion by comparing significant protein findings (e.g., MSMB, SERPINA3) with results from existing functional studies and multi-omics datasets and unravelling new insights.</p><disp-quote content-type="editor-comment"><p>(4) Colocalization - seems clear to me.</p><p>(5) Additional post-GWAS analyses (pathway + druggability) - again, the analyses seem to be performed appropriately, although little additional insight other than the reporting of output from the methods.</p></disp-quote><p>The post-MR druggability and pathway analyses serve two primary scientific purposes: (1) therapeutic prioritization - systematically evaluating which MR-identified proteins represent tractable drug targets (either through existing FDA-approved agents or compounds in clinical development) with direct relevance to cancer or PCa management, and (2) mechanistic hypothesis generation - mapping these candidate proteins to coherent biological pathways to guide future functional validation studies investigating their causal roles in prostate carcinogenesis. In response to your feedback, we have restructured the Discussion section under the subheading “Biological Mechanisms and Druggable Targets” to synthesize these findings, explicitly linking biological pathway to therapeutic targets.</p><disp-quote content-type="editor-comment"><p>Minor points:</p><p>(6) The stated motivation for this work is &quot;early detection&quot;. But causality isn't necessary for early detection. If the authors are interested in early detection, other analysis approaches are more appropriate.</p></disp-quote><p>We appreciate your insightful feedback. Early detection is one motivation for this work, meanwhile, our goal is also to identify causally implicated proteins that may serve as intervention targets for PCa prevention or therapy. Establishing causality is critical for distinguishing biomarkers that drive disease pathogenesis from those that are secondary to disease progression, as the former holds greater specificity for early detection and prioritization of therapeutic targets. While we acknowledge that validation for early detection may require additional methodologies, MR analysis provides a foundational step by prioritizing candidate proteins with causal links to disease. This approach ensures that downstream efforts focus on biomarkers and targets with the greatest potential to alter disease trajectories, rather than merely correlative markers.</p><disp-quote content-type="editor-comment"><p>(7) The authors state &quot;193 proteins were associated with PCa risk&quot;, but they are looking at MR results - these analyses test for disease associations of genetically-predicted levels of proteins, not proteins themselves.</p></disp-quote><p>True, in MR, the exposure of interest is the lifelong effect of genetically predicted protein levels. This approach is designed to infer causality while avoiding confounding and reverse causation, as genetic variants are fixed at conception and unaffected by disease processes. When we state “193 proteins were associated with PCa risk,” we specifically refer to proteins whose genetically predicted levels (based on instrument SNPs from protein QTLs) show causal links to PCa. Importantly, MR does not measure the direct association between observed protein concentrations and disease. Instead, it estimates the lifelong causal effect of protein levels predicted by genetics. This distinction is critical for disentangling cause from consequence. For example, a protein elevated due to tumor progression would not be identified as causal in MR if its genetic predictors are unrelated to PCa risk.</p><p>We acknowledge that clinical translation requires further validation of these proteins in observational studies measuring actual protein levels. However, MR provides a robust first step by prioritizing candidates with causal roles, thereby reducing the risk of investing in biomarkers confounded by disease processes.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>As outlined above, the major weakness of the manuscript is its failure to consider BPH / LUTS, and whether the markers and targets are specific to PCa or not. Specific improvements that the authors could consider might include a literature review of the features identified for their 20 high-risk proteins, and ideally also analyze whether these proteins are upregulated or downregulated in the databases they have analysed (for example it will be easy to analyze whether these proteins are dysregulated in BPH patients as these are specifically identified in the UK Biobank).</p><p>The authors may be able to gain context for this approach by looking at papers analyzing BPH and the complement cascade and other proteins from the authors' top 10 or top 20, for example: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/pros.24639IF">https://doi.org/10.1002/pros.24639IF</ext-link> : 2.6 Q2</p><p>Other sources can be identified by examining the literature for recent omics papers analysing BPH, especially those that analyse and compare BPH / PCa specifically.</p></disp-quote><p>Thank you for highlighting the critical need to distinguish PCa-specific biomarkers from those shared with BPH. In response, we conducted a literature review of multi-omics datasets and prospective cohort studies, systematically evaluating the specificity of prioritized proteins by comparing their expression trends in PCa and BPH or benign prostate tissues. These findings are now integrated into the revised Discussion section under the subheading &quot; Plasma Proteins Causal Links to Prostate Cancer&quot;.</p><disp-quote content-type="editor-comment"><p>In the Discussion, the paragraph (line 288) on PSA is extremely weak. The authors state that further research is needed, and yet only reference four articles (from 2008, 2010, 2012, 2014), none of which are from the last decade. Considerable amounts of research from the last ten years have been published on PSA, for example, see this article from 2018, which specifically analyses PSA in the context of the UK Biobank. This section should be made more up-to-date with the latest literature findings. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-018-06920-9">https://doi.org/10.1038/s41467-018-06920-9</ext-link></p></disp-quote><p>Thank you very much for your feedback. We acknowledge the need to strengthen the discussion on PSA by incorporating recent literature. In the revised manuscript, we have expanded the PSA discussion to integrate contemporary research on the prognostic role of PSA in the progression of PCa and its limitations in cancer screening, ensuring that our discussion reflected the current consensus and controversies.</p><disp-quote content-type="editor-comment"><p>Also in the Discussion, the analysis of phenotypic indicators is insufficiently comprehensive and should reference other recent research. For example, this recent UK Biobank study dealt with a wide range of conditions, including prostate cancer, and identified similar factors to those identified in this paper. The authors should compare and contrast their phenotypic findings with the existing literature. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41588-024-01898-1">https://doi.org/10.1038/s41588-024-01898-1</ext-link></p></disp-quote><p>Thank you for addressing the comprehensiveness of phenotypic analysis. We have learned recent large-scale phenome-wide analyses (linked in your feedback) that explore multi-omics biomarkers and their associations with a range of different diseases. We have compared and contrasted our phenotypic findings with the existing literature and revised the Discussion section to interpret phenotype-PCa associations, emphasizing both shared pathways and disease-specific signals.</p><disp-quote content-type="editor-comment"><p>Under Methods, there is too little information on how Controls were selected, whether any matching process was conducted, or whether there are fundamental differences between the cases and controls (such as smoking status, BMI, comorbidities). The authors use R, and a library such as MatchIt could be used to ensure that the Controls cohort is appropriately matched to the Cases.</p></disp-quote><p>As outlined above, we acknowledge that our original analysis did not directly address this critical issue due to a key data limitation. The publicly available GWAS summary statistics for PCa (from openGWAS and FinnGen) do not provide individual-level data on covariates, resulting in no direct assessment of demographic or clinical differences between cases and controls.</p><disp-quote content-type="editor-comment"><p>An important final point is that, as far as I can tell, no UK Biobank Application Number has been specified in the manuscript. This is vital to establish that there was an original hypothesis being investigated (as opposed to data dredging of open access resources), especially in light of the largely mechanistic flow of the manuscript and lack of PCa and relevant confounder-specific discussion. The authors may be aware of the work of Stender et al (2024) regarding formulaic papers using Mendelian randomization, especially that &quot;[All] combinations of exposure and outcome results based on data available in IEU openGWAS (<ext-link ext-link-type="uri" xlink:href="https://gwas.mrcieu.ac.uk/">https://gwas.mrcieu.ac.uk/</ext-link>) can be browsed online on <ext-link ext-link-type="uri" xlink:href="http://epigraphDB.org">epigraphDB.org</ext-link>. In other words, these results are, in effect, already published. Reporting them again in a scientific paper adds nothing to what can be looked up online in minutes.&quot; The authors may wish to address this issue directly.</p><p>Stender, S., Gellert-Kristensen, H. &amp; Smith, G.D. Reclaiming Mendelian randomization from the deluge of papers and misleading findings. Lipids Health Dis 23, 286 (2024). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12944-024-02284-w">https://doi.org/10.1186/s12944-024-02284-w</ext-link></p></disp-quote><p>We confirm that all data used in this study were obtained from publicly available GWAS summary statistics (e.g., PRACTICAL consortium, FinnGen) and proteomic datasets (deCODE, UKB-PPP). Our research was guided by a predefined hypothesis to investigate causal plasma protein biomarkers for prostate cancer, rather than exploratory data mining. The analytical pipelines and integrative approaches (e.g., colocalization, druggability assessment) were specifically designed to address this hypothesis, aligning with the ethical use of open-access resources.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>There are several specific recommendations in the public review (e.g., clarify the contribution of the GWAS). Otherwise, there is nothing clearly incorrect, but translational insight is missing - the analyses are not clearly connected to the scientific literature. This is a limitation rather than a flaw - the manuscript will likely still be useful to readers.</p></disp-quote><p>We thank you for highlighting the need to strengthen translational insights and contextualize our findings within existing literature. In the revised manuscript, we have expanded the Discussion section to systematically compare our results with prior mechanistic and clinical studies, including the shared pathways of associated phenotypes, the potential of significant proteins in biomarkers and therapeutic targeting. These revisions ensure our analyses are firmly rooted in the scientific literature.</p></body></sub-article></article>